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ABSTRACT
Reversible and covalent post-translational modification (PTM) of proteins by small
ubiquitin-related  modifier  (SUMO-1,  -2,  and  -3)  is  an  essential  process  occurring  in  all
mammals. SUMOylation can affect the target protein´s localization as well as its
interactions, stability and activity and in that way it has a regulatory role in many biological
functions, including transcription, DNA repair and replication. The androgen receptor (AR)
is a well known SUMO target. The AR is a transcription factor (TF) that mediates the effects
of androgenic hormones at the level of gene regulation. These androgen-regulated genes
are critical in the development and maintenance of the male sexual phenotype, thus they
influence the prostate gland. Prostate cancer (PCa) is a serious health concern of men and it
is  strongly  dependent  on  AR  signaling.  Thus,  the  AR  is  a  major  druggable  target  in
advanced PCa. The aim of this thesis was to study the role of SUMO-modification on AR-
dependent transcription in the natural chromatin environment in PCa cells. Due to its
cooperative  role  with  AR,  FOXA1  has  been  extensively  studied  and  linked  to  PCa
development.  However,  surprisingly  little  is  known about  the  PTMs of  FOXA1,  and thus
one aim was to study the impact of the SUMO-modification on FOXA1 function. In this
thesis, genome-wide gene expression analyses with stable PCa cell lines expressing wild-
type AR (wt-AR) or SUMOylation-deficient AR (AR-2KR) revealed that SUMOylation
modulates the AR function in a target gene and pathway selective manner. Moreover,
genome-wide AR binding analyses (ChIP-seq) indicated that SUMOylation could regulate
the AR´s chromatin occupancy, which may partially explain the differential expression
between the wtAR and AR-2KR cells on many target loci. The difference in enriched motifs
in de novo motif analyses indicated that SUMOylation may regulate the interactions of the
AR  with  other  TFs,  including  FOXA1.  In  PCa  cells,  the  level  of  endogenous  AR
SUMOylation,  SUMO2/3  conjugation  in  particular,  was  enhanced  by  androgens  or  cell
stress.  In  addition,  cell  stress  altered  AR´s  intranuclear  distribution  and  detached  the  AR
from chromatin, repressing AR-dependent transcription in a reversible manner. These
results suggest that cell stress-induced SUMO-2/3 modifications can protect the AR from
misfolding and degradation, whereas the basal level modifications are linked to the activity
cycles  of  the  hormone-bound  receptor  in  the  nucleus.  FOXA1  is  SUMOylated  and
SUMOylation  modulated  both  AR  and  FOXA1´s  stability  and  nuclear  mobility.
Additionally, SUMOylation seemed to enhance FOXA1´s chromatin occupancy and
transcriptional activity, which modulated the ability of FOXA1 to collaborate with the AR.
In summary, this thesis has yielded new information concerning how SUMOylation of the
AR and FOXA1 modulates androgen-regulated gene expression in PCa cells. These results
could provide, in the long run, new prospects for PCa therapy.
National Library of Medicine Classification: QU 55, QU 475, WJ 762, WK 150
Medical Subject Headings: Protein Processing, Post-Translational; Sumoylation; Small Ubiquitin-Related
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TIIVISTELMÄ
SUMO-muokkauksessa pieni ubikitiinia muistuttava proteiini (small ubiquitin-like
modifier, SUMO-1,-2,-3) liitetään kovalentisti kohdeproteiinin spesifiseen lysiinitähteeseen.
SUMOlaatio voi vaikuttaa kohdeproteiininsa sijaintiin, vuorovaikutuksiin, pysyvyyteen ja
aktiivisuuteen. Yhä useamman proteiinin on osoitettu SUMOttuvan, ja SUMOlaatio onkin
elintärkeä biologisten toimintojen, kuten transkription ja DNA-korjauksen, säätelijä.
Androgeenireseptori (AR) on eräs SUMOlaation kohdeproteiineista. AR on
transkriptiotekijä, joka välittää androgeenien eli mieshormonien vaikutukset geenien
luentaan. Androgeenillä säädellyt geenit ovat tärkeitä miehisten kehonpiirteiden ja -
toimintojen, kuten eturauhasen, kehityksessä ja ylläpidossa. AR:lla on tärkeä rooli myös
eturauhassyövässä, joka on yleisin miesten syöpätyyppi Suomessa. AR onkin merkittävä
eturauhassyövän lääkinnällisen hoidon ja lääkekehityksen kohde. Väitöskirjatyön
tavoitteena oli selvittää ne mekanismit, joilla SUMOlaatio säätelee AR:n toimintaa
normaalissa kromatiiniympäristössä eturauhassyöpäsoluissa. Lisäksi väitöskirjatyön
tavoitteena oli selvittää AR:n kanssa toimivan pioneeritekijän, FOXA1:n, mahdollisen
SUMO-muokkauksen vaikutus sen toimintaan. Väitöskirjatyössä stabiilisti AR:a ja sen
SUMOlaatioon kykenemätöntä mutanttia ilmentävillä solulinjoilla tehdyt genominlaajuiset
geeninluentamittaukset osoittivat, että AR:n SUMO-muokkaus vaikuttaa androgeenillä
säädeltyjen geenien ilmentymiseen kohdegeenispesifisesti eli eri geeneillä on erilainen
herkkyys AR:n SUMOlaatiolle. SUMOlaation vaikutuksesta eri tavalla säädellyt geenit
liittyivät mm. solukasvuun. SUMO-muokkauksen huomattiin vaikuttavan myös genomin
laajuisesti AR:n kromatiiniin sitoutumiseen, mikä osittain selitti edellä mainitut geenien
ilmentymisen erot. Sitoutumispaikkojen de novo-motiivianalyysin mukaan SUMO-
muokkaus voi vaikuttaa AR:n vuorovaikutukseen muiden transkriptiotekijöiden, kuten
FOXA1:n, kanssa. Androgeenillä säädeltyjen geenien ilmentymiseen vaikuttaa myös
solustressi, kuten kohonnut lämpötila, joka lisäsi voimakkaasti ja nopeasti AR:n SUMO-
muokkausta ja esti AR:n sitoutumisen kromatiiniin. Solustressin vaikutukset olivat
palautuvia. Solustressi muutti myös AR:n tumansisäistä sijaintia. Myös FOXA1
SUMOloituu, mikä vaikuttaa androgeenillä säädeltyjen geenien ilmentymiseen
muuttuneen AR-FOXA1 yhteistyön kautta.  SUMO-muokkaus muutti AR:n ja FOXA1:n
stabiilisuutta ja liikkuvuutta tumassa. Yhteenvetona voidaan todeta että väitöskirjatyöni on
lisännyt ymmärrystä SUMO-muokkauksen roolista geenien ilmentymisen säätelyssä,
varsinkin AR:n ja FOXA1:n toiminnassa eturauhassyöpäsoluissa. Tutkimuksemme
paljastavat uusia mahdollisuuksia säädellä AR:n aktiivisuutta ja eturauhassyöpäsolujen
kasvua, mistä voi olla hyötyä uusien ja tehokkaampien lääkeaineiden kehittämistyössä.
Luokitus: QU 55, QU 475, WJ 762, WK 150
Yleinen Suomalainen asiasanasto: proteiinit; muokkaus; reseptorit; androgeenit; transkriptio (biologia);
geeniekspressio; syöpäsolut; eturauhassyöpä
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1 Introduction
The release of the human genome sequence in 2001 revealed a much lower protein-coding
gene  count  than  expected  and  thus  it  became  abundantly  clear  that  the  number  of  genes
could no longer be considered to account for the complexity of the organism. Instead, it
appears to be the regulation of the expression of human genetic information which
accounts for the complexity i.e. only approximately 1% of human genome represents the
protein coding region, the remaining overwhelming proportion of the genome has a
regulatory function. The regulation of gene expression is a highly temporally and spatially
regulated process, with certain genes being expressed only in certain cells at certain
moments. Scientists are still trying to understand the exact rules of gene regulation, e.g.
how  it  is  altered  during  aging,  cancer  or  drug  administration.  Understanding  how  genes
are regulated could help to discover new cures for many potentially fatal diseases, such as
cancer.
Transcription factors (TFs) are proteins that bind to specific DNA sequences and control
the transcription of genetic information (genes) from DNA to messenger RNA and thereby
regulate the amount of proteins in our cells. The androgen receptor (AR) is a hormone-
controlled TF, whose mediated transcription is a complex multi-step process. Androgen
binding activates AR by inducing a conformational change, followed by homodimerization
and nuclear translocation of the receptor. Once within the nucleus, AR binds to its response
elements at regulatory regions of its target genes with the guidance of so-called pioneer
factors, such as forkhead box A1 (FOXA1). When it has bound to the target gene, it can
either activate or repress gene transcription. In addition to androgen binding, AR-mediated
transcription involves the coordinated recruitment of many collaborating TFs and
coregulators in a precise temporal and spatial manner.  It seems to be the coregulators that
ensure the transcriptional outcome, e.g. by facilitating access to binding sites on chromatin
and bridging the proximal and distal components needed for transcription.
The  AR  is  needed  for  normal  development  and  the  maintenance  of  the  prostate  gland
but it is recognized that prostate cancer (PCa) is strongly dependent on AR signaling. Thus,
the AR is the major druggable target for the advanced disease. In spite of extensive and on-
going  basic  research  into  PCa  biology,  many  of  the  basic  mechanisms  involved  in  the
regulation of the AR are still unclear and there is no curative treatment for antihormone
resistant  cancer.  Therefore,  PCa  continues  to  pose  a  major  challenge  not  only  in  terms  of
treatment but also with respect to diagnosis.
Post-translational modifications (PTMs), including small ubiquitin-related modifier
protein  (SUMO)  modification,  can  regulate  many  biological  processes,  including
transcription, for example when the AR is SUMOylated, its transcriptional activity is
altered.  SUMOylation  is  a  reversible  and  bulky  modification  in  which  SUMO-1,  -2,  or  -3
becomes attached to its target protein´s specific lysine residues via an enzymatic pathway
analogous to ubiquitylation but with its own distinct enzymes. SUMOylation is essential for
normal  physiology  of  living  organisms  and  it  is  linked  to  many  pathological  events  in
humans. For instance, aberrant expression levels of the SUMOylation pathway proteins
have been associated with cancer. Previously, SUMO-modification has been linked to
transcriptional repression, but recent genome-wide studies of SUMOylated transcriptional
regulators and the global role of SUMO on chromatin have revealed that this modification
has a more diversified role in the regulation of transcription.
The goal of this doctoral thesis was to investigate how SUMOylation could regulate AR
and FOXA1 function in PCa cells. This thesis showed that SUMOylation had an impact on
AR and FOXA1 stability, intranuclear mobilities and chromatin binding and thus
SUMOylation can modulate androgen-regulated gene expression via many mechanisms.
2
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2.1 SMALL-UBIQUITIN LIKE MODIFICATION
Proteins are the chief actors within the cell and their action is often reversibly and rapidly
modified  by  PTMs.  The  diversity  and  number  of  PTMs  increase  the  complexity  of  the
proteome by several orders of magnitude. These modifications involve the attachment of
functional groups onto the amino acid side chains of the target protein. The attachment
group can be a small chemical moiety (e.g. phosphate, acetyl, methyl), lipid, carbohydrate
or a small protein, such as ubiquitin or ubiquitin like protein (UBL) (van Laar et al. 1990,
Poukka et al. 2000, Fu et al. 2003, Kinyamu et al. 2005, Ko et al. 2011, Coffey & Robson 2012,
Minquez et al. 2012).  In this way, PTMs can change and regulate the function of the target
proteins. The PTMs can regulate a protein’s activity, stability and localization and in this
manner, they can modulate many fundamental cellular processes, such as protein-protein
interactions, gene regulation and protein degradation.
SUMO is one of the UBLs and it shares a similar three dimensional structure (ubiquitin
fold) with other members of this family (van der Veen & Ploegh 2012). As with other UBLs,
SUMO is reversibly and covalently conjugated to its target proteins' specific lysine residues
via an enzymatic SUMOylation pathway analogous to ubiquitylation but with catalyzing
enzymes that are unique to SUMOylation (summarized in Figure 1) (Flotho & Melchior
2013, Hay 2013). SUMO was discovered in 1996; Ran GTPase activating protein 1 was the
first SUMO target identified (Matunis et al. 1996). Since its discovery, SUMOylation targets
and their functional consequences have been a topic of great interest.
Mammals express three functional SUMO proteins: SUMO2 and SUMO3 are almost
identical (differing only in three N-terminal residues) and SUMO2/3 is ~47 % identical to
SUMO1 (Hay 2005).  Due to their almost identical sequences, the currently available
antibodies cannot distinguish between SUMO2 and -3 paralogs (this explains the often
mentioned SUMO2/3 terminology). All SUMO proteins are small (~10 kDa) and all three
SUMO paralogs are expressed in multiple tissues, with SUMO2/3 being generally more
expressed than SUMO-1 in most tissues (Saitoh & Hinchey 2000, Rytinki et al. 2012). In
particular, there seems to be a larger pool of non-conjugated SUMO2/3 than SUMO1,
because  SUMO1  primarily  exists  in  the  conjugated  form.  Moreover,  SUMO2/3  is  more
rapidly cleaved from conjugates than SUMO1 (Kolli et al. 2010). Some target proteins are
uniquely modified with one SUMO paralog, but the mechanistical basis for the SUMO
paralog preference is not understood and SUMO substrates show considerable overlap
(Poukka et al. 2000, Vertegaal et al. 2006). The clearest difference between paralogs is in the
chain formation and response to stress (stress described in greater detail in the chapter
2.1.5). SUMO2/3 can form chains between C-terminal glycine and internal SUMOylation
site  lysine  (lysine  11;  possibly  to  other  lysines  as  well)  and  in  this  way,  polySUMOylate
particular proteins (Tatham et al. 2001, Matic et al. 2008). As a similar attachment site is not
present in SUMO1, it does not form chains efficiently and it may act as a SUMO chain
terminator (Matic et al. 2008). Increased SUMO chain formation has been implicated in
various forms of cell stress, maintenance of chromatin structure and SUMO-targeted
protein degradation (Golebiowski et al. 2009, Srikumar et al. 2013, Sriramachandran &
Dohmen 2014). Thus, the modification by SUMO1 and SUMO2/3 may have distinct
functional consequences.  In addition, recent ChIP-seq studies have shown that SUMO1
and SUMO2 display unique genome-wide binding patterns on chromatin (described in
greater detail in the chapter 2.1.4) (Neyret-Kahn et al. 2013, Niskanen et al. 2015).
4Figure 1. The SUMO-modification cycle.  Before attachment to proteins,  SUMO is  processed by
the  SUMO-specific  proteases  (SENP)  to  expose  a  diglycine  (GG)  motif.  Processed  SUMO  is
activated by conjugation to cysteine (C) residues in SUMO-activating enzymes (SAE1/2).
SAE1/2 enzyme transfers SUMO to a conjugating enzyme (Ubc9),  which in turn enlists  an E3
ligase  to  help  deliver  SUMO  to  the  intended  target  protein  lysine  (K)  residue.  SUMO  can  be
removed  from  target  proteins  by  the  SENPs.  RNF4,  a  SUMO-targeted  ubiquitin  ligase,  can
recognize SUMO-modified proteins and direct them to proteasomal degradation (S1; SUMO1,
S2; SUMO2, Ub; ubiquitin).
2.1.1 SUMOylation pathway
All SUMO proteins are activated and conjugated by the same enzymes (Wilkinson &
Henley 2010, Flotho & Melchior 2013). The first step in the SUMO pathway is SUMO
maturation. Nascent SUMOs are activated when SUMO-specific proteases (SENPs) remove
amino acids  from the  SUMO C-terminus (four  in  SUMO1),  exposing two glycines  (Figure
1). Maturated SUMO is activated by the E1 heterodimer (formed of SUMO activating
enzymes [SAE] 1 and 2) (Schulman & Harper 2009). SAE2´s catalytic cysteine (the
sulphydryl  group)  forms  a  thiester  bond  to  the  C-terminal  glycine  of  SUMO,  forming  a
thioester-linked SUMO-E1 intermediate (Tatham et al. 2001). Subsequently, SUMO is
transferred to the catalytic cysteine on the E2 enzyme (Ubc9) by transthiolation. Finally,
SUMO E3 ligase promotes the transfer of SUMO from Ubc9 to the target protein. E3
recognizes the target proteins and promotes the formation of the isopeptide bond between
5the target protein lysine (?-amino group) and the C-terminal glycine of SUMO.
SUMOylation is reversible and SUMO can be removed from target proteins by SENPs,
some of which are also needed for maturation. The proteases cleave the isopeptide bond
between the SUMO and the target protein and release SUMO for further cycles (Hay 2007,
Yeh 2009). DeSUMOylation determines steady-state SUMOylation of individual target
proteins.
2.1.2 SUMOylation enzymes
SUMOylation is a highly dynamic process although in comparison with ubiquitylation, the
SUMOylation pathway utilizes a much more limited number of enzymes. SUMOylation
involves an E1, an E2 (Ubc9) and ~10 E3 ligases, whereas ubiquitylation has ~35 different E2
conjugating enzymes and over 600 E3 ligases (van Wijk & Timmers 2010). SUMO E3 ligases
enhance the SUMOylation rate and they may contribute to substrate specificity. The largest
group  of  E3  ligases  is  the  family  of  PIAS  (protein  inhibitor  of  activated  STAT,  signal
transducer and activator of transcription) proteins. The PIAS family contains five members,
PIAS1, -2 (-x?, -x?), -3, -4 (y); these have a high degree of sequence homology and contain
five distinct conserved domains/motifs (Palvimo 2007, Rytinki et al. 2009).  In addition to
SUMO  E3  ligases,  PIAS  proteins  are  important  regulators  of  many  cellular  functions;  for
example PIAS family members have been shown to interact with AR and to influence AR-
dependent transcription (Kotaja et al. 2000, Toropainen et al. 2015). Other E3 ligases, such
as nucleoporin RANBP2, the polycomb group protein Pc2 and CBX4, seem to have a more
limited number of targets (Pichler et al. 2002, Kagey et al. 2003).
SUMO-specific cysteine proteases catalyze the deconjugation of SUMO and the
activation of the SUMO precursor proteins. In contrast to the 100 known ubiquitin
deconjugases, only nine SUMO isopeptidases have been identified to date. DeSUMOylases
have been classified into three distinct families: SENP family, DeSUMOylation isopeptidase
(Desi1,-2) family and ubiquitin-specific peptidase-like protein (USPL1) family (Nayak &
Muller 2014). Human cells express six SENP family members, SENP1, -2, -3, -5, -6, -7; they
contain a conserved catalytic domain in their C-terminal region and the nuclear localization
signal in their N-terminus (Yeh 2009, Nayak & Muller 2014). SENPs have paralog
preferences in terms of maturation and deconjugation: SENP3 and -5 favor SUMO2/3
deconjugation, SENP1 and 2 target maturation of all SUMOs and deconjugate all SUMOs,
whereas SENP6 and -7 are involved in chain editing (Zhang et al. 2002, Di Bacco et al. 2006,
Yeh 2009). Desi enzymes deconjugate all SUMOs but do not have any SUMO-processing
activity. The transcription repressor BZEL is the only Desi substrate identified to date (Shin
et al. 2012). USPL1 is active in maturation and deconjugation and it is an essential Cajal
body component (Schultz et al. 2012).
2.1.3 SUMO targets
SUMO enzymes are enriched in the cell  nucleus. Thus, most of the SUMO target proteins
are found in or near to the nucleus. The detection of SUMOylation can be challenging due
to the rapid cycles of SUMOylation and deSUMOyaltion, which usually leads to a very low
level of endogenous modified protein. In addition, many proteins can be SUMOylated only
in response to stimuli (e.g. ligand binding, PTMs). SUMOylated proteins have been
traditionally  identified  with  mutation  analyses  based  on  conserved  lysines  and  SUMO-
interaction motifs (SIMs), but new, proteome-wide studies have helped in target
identification (Golebiowski et al. 2009, Tammsalu et al. 2014, Hendriks et al. 2014). These
studies have used new proteomic techniques, such as stable isotope labeling by amino acids
in cell culture (SILAC) or endogenously expressed epitope-tagged SUMO with affinity-
purification combined with high-resolution mass spectrometry. In this way, hundreds of
new SUMOylation targets have been identified in addition to the hundreds of those
previously  known.  A protein  can be  SUMOylated,  if  it  can interact  with the Ubc9-SUMO
intermediate or can be recognized by E3 ligase. Ubc9 can recognize a short motif in target
proteins, the SUMO consensus site. The classical consensus motif is ?KxE/D, where ? is a
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amino acid, E is glutamic acid and D is aspartic acid (Rodriguez et al. 2001). Recent
unbiased, proteome-wide, SUMOylation site studies have indicated that SUMOylation
primarily  (more  than  70  %)  occurs  on  proteins  with  a  forward  or  inverted  consensus
sequence (mainly ?KxE) (Tammsalu et al. 2014). Interestingly, nearly half of the SUMO-
target proteins contain a single SUMOylation site, although some proteins have over 20
sites (maximum 40 sites)(Hendriks 2014). The target protein, like promyelocytic leukemia
protein (PML) or Daxx, can recruit directly the Ubc9-SUMO intermediate with SIM but
without the help of E3 ligases and become SUMOylated. SIM enables noncovalent SUMO
binding and it consists of a hydrophobic core (I/V-X-I/V-I/V) that forms a ?-strand that can
be inserted between the ?-helix and ?-strand of SUMO (Song et al. 2004). In addition, many
E3 ligases contain SIMs and can mediate protein noncovalent binding to SUMO.
SUMOylation seems to have a regulatory effect on almost every cellular process. This is
achieved by modulation of target protein function: SUMOylation can mask an interaction
surface (e.g. prevent TFs from binding to chromatin, block protein-protein interactions), or
conversely create a SUMO-dependent interaction with downstream effectors. In addition,
SUMOylation can induce conformational changes. Thus, unlike ubiquitination,
SUMOylation does not target proteins for degradation. SUMOylation alters the function of
proteins involved in diverse cellular processes such as cell cycle, chromatin organization,
transcription, DNA repair, protein homeostasis and trafficking (Heun 2007, Galanty et al.
2009, Gareau & Lima 2010, Wilkinson & Henley 2010). Similarly, SUMOylated proteins
include numerous TFs. The AR was the first identified SUMOylated SR, but later also GR
and PR have been shown to be SUMOylated (Poukka et al. 2000, Tian et al. 2002, Treuter &
Venteclef 2011, Knutson et al. 2012). AR SUMOylation sites are located in the ligand-
independent transactivation domain (NTD) (i.e. lysines 386 and 520) (Figure 2). Lately the
role of SUMOylation on SR´s function has been investigated in an unbiased genome-wide
fashion (Knutson et al. 2012, Paakinaho et al. 2014). The first reports of SUMOylated TFs
suggested that SUMOylation was associated with transcriptional repression, but new
studies have tended also to link SUMOylation to active transcription (Paakinaho et al. 2014,
Niskanen et al. 2015).
2.1.4 SUMOylation at chromatin
Recent studies have clarified to some extent the global chromatin binding dynamics of the
SUMOylation machinery components (Neyret-Kahn et al. 2013, Paakinaho et al. 2014,
Niskanen et al. 2015, Toropainen et al. 2015). These genome-wide ChIP-seq studies have
revealed that not only SUMO proteins, but also PIAS proteins (PIAS1 and PIASY) and Ubc9
are  present  on  chromatin.  Localization  is  widely  distributed  over  the  genome  and  the
majority  of  these  binding  sites  are  located  in  intergenic  and  intron  regions.  The  more
widely  expressed  SUMO2/3  form  seems  to  have  more  binding  sites  than  SUMO1  and
interestingly, many SUMO1 binding sites are free from SUMO2/3 and vice versa.
Accordingly, there seem to be genomic sites with specificities for each SUMO paralog.
SUMO  binding  sites  are  narrow  chromatin  regions,  suggesting  that  the  SUMO  signals
derive from SUMOylated TFs on chromatin. Similarly, de novo motif  analysis  of  SUMO
binding sites identified multiple TF binding motifs. The overlap between TF and SUMO2/3
data indicates that SUMOylated TFs bind to chromatin and SUMOylation can regulate
protein-protein interactions at TF complexes (Niskanen et al. 2015). The comparison of
SUMO2/3 binding sites in different cells indicates that the majority of SUMO2/3 binding
sites are cell type-specific. Generally SUMO binding seems to have a strong association to
active promoters. The highest levels of SUMO are found in the vicinity of promoters of
histone and biogenesis genes, where SUMO seems to act as a major negative regulator of
gene expression (Neyret-Kahn et al. 2013). Interestingly, promoters of histone genes are co-
occupied by SUMOylation machinery components, whereas most SUMO binding sites are
devoid of PIAS and Ubc9 (Neyret-Kahn et al. 2013, Toropainen et al. 2015).
72.1.5 Biological consequences of SUMOylation
SUMO2/3 conjugation helps cells to survive from heat shock (HS) (Saitoh & Hinchey 2000,
Golebiowski et al. 2009, Niskanen et al. 2015). A global comparison of the SUMO proteome
before and after HS indicated that cellular stress,  such as HS, causes rapid global SUMO2
redistribution between substrates (Golebiowski et al. 2009, Tammsalu et al. 2014). HS
especially stimulates the polymerization of SUMO proteins and accumulation of very high
molecular weight SUMO conjugates. Interestingly, SUMOs can also become deconjugated
during  HS  and  thus,  HS  changes  the  composition  of  the  SUMOylated  proteome.  Those
proteins which lost their SUMO during HS did not re-SUMOylate during the recovery
period. Furthermore, deconjugation during the recovery period is much slower than
conjugation during stress. In addition, HS can induce a global redistribution of SUMO2/3
on chromatin, mostly through increased occupancy at the promoter and enhancer regions,
which are active in transcription. Interestingly, HS also triggered a dynamic chromatin
binding of SUMO ligase PIAS1 (Niskanen et al. 2015).
Due to its role in many crucial cellular processes, SUMOylation is essential for normal
physiology  of  living  organisms.  In  most  organisms,  one  SUMO  paralog  can  be
compensated by others, and in mouse only the presence of SUMO2 is essential (Evdokimov
et al. 2008, Zhang et al. 2008a, Wang et al. 2014). Similarly, Ubc9 is essential and Ubc9
deletion in mouse leads to embryonic death, which highlights the significance of this
pathway during embryonic development (Nacerddine et al. 2005). Additionally, knockout
of  either  SENP1  or  SENP2  is  also  embryologically  lethal  and  deletion  of  E3  ligases  in
knockout mice impairs normal mouse development (Roth et al. 2004, Santti et al. 2005,
Cheng et al. 2007, Kang et al. 2010). Thus, SUMOylation seems to be essential, especially for
proliferating cells and targeting the SUMOylation pathway could be a useful tool in cancer
therapy. Changes in the amount of SUMOylation enzymes have been found to correlate
with tumor development (Bawa-Khalfe & Yeh 2010, Bettermann et al. 2012). Elevated
SENP1 and SENP3 expression levels have been observed in PCa and linked with PCa
development and enhanced deSUMOylation of cellular substrates (Cheng et al. 2006).
Those  breast  cancers  with  high  levels  of  Myc  in  the  tumors  and  a  low  expression  of  E1
(SAE1/2) display a less aggressive clinical behavior (Kessler et al. 2012). SUMOylation of a
single protein can exert critical downstream consequences; for example mutation in the
SUMO consensus site of microphthalmia-associated TF (MITF) impairs its SUMOylation
and increases its transcriptional activity on a subset of genes associated with a
predisposition to melanoma and renal carcinoma (Bertolotto et al. 2011). Furthermore,
disruption of SUMOylation of steroidogenic factor 1 (SF-1) in mice via a knock-in approach,
resulted in abnormal Hedgehog signaling and disrupted endocrine tissue development and
function (Lee et al. 2011).
2.1.6 Interplay of SUMO with other PTMs
PTMs  have  been  mostly  studied  as  individual  events,  although  it  is  clear  that  the
modifications interact with each other. It is this combination of modifications which confers
the subtle complexity of PTMs in the ways through which they can regulate the functions of
their target proteins. Notably, the SUMOylation of some target proteins requires
phosphorylation of serine or threonine close to the SUMO consensus site. The
phosphorylation-dependent SUMOylation motif which contains a proline-directed
phosphorylation site separated by two amino acids of a SUMO consensus site, is found in
many TFs, such as in heat-shock factors and GATA-1 and their coregulators (Hietakangas et
al. 2006).
Many SUMOylated lysines have been shown to be also methylated, acetylated or
ubiquitinated and these PTMs can compete for the same lysine residues. Interestingly, there
can be also cross-talk between SUMO and ubiquitin modifications: SUMO-targeted
ubiquitin E3 ligases (STUbLs) recognize polySUMOylated proteins and target them for
degradation by the proteasome (Figure 1) (Sriramachandran & Dohmen 2014). Thus,
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really interesting new gene (RING) finger domains for ubiquitin ligase activity and SIMs to
recognize their SUMOylated substrates. RING finger protein 4 (RNF4) and 11 (Arkadia) are
STUbLs identified in humans (Häkli et al. 2004, Sun et al. 2007, Sun & Hunter 2012).
Interestingly, RNF4 was first identified as a co-regulator for SR (Moilanen et al. 1998). RNF4
contains  four  putative  SIMs,  two  of  which  are  necessary  and  sufficient  to  achieve  the
SUMO-interaction and thus RNF4 preferentially binds to chains with a length of at least 3
SUMOs (Keusekotten et al. 2014). The PML was the first identified RNF4 target (Häkli et al.
2005, Tatham et al. 2008). Interestingly, chromosomal translocation produces oncogenic
fusion protein of PML and the retinoic acid receptor ? which is found in acute
promyelocytic leukemia (APL) (de The et al. 2012). APL patients can be treated with arsenic
trioxide which induces polySUMOylation of the PML, RNF4-mediated ubiquitylation and
degradation of the oncoprotein. Recently, the SUMO deconjugase SENP1 was shown to be
also critical for the response (Fasci et al. 2015).
2.2 ANDROGEN RECEPTOR
The androgens, testosterone or 5?-dihydrotestosterone (DHT), play an important role
throughout life: they are responsible for the development of the male phenotype in the
embryo, sexual maturation at puberty and the maintenance of the male reproductive
organs in adulthood. AR´s fundamental role for normal male sexual differentiation and
reproductive function has been demonstrated with AR knockout mouse models and in
patients suffering from the androgen insensitive syndrome (AIS) (Wang et al. 2009a,
Jääskeläinen 2012). Global AR knockout male mice, similarly as complete AIS-suffering
patients, have female external genitalia and are infertile (lack of normal spermatogenesis)
(Yeh et al. 2002). The AR also plays an important role in female reproduction, as global AR
knockout female mice display changes in fertility, ovarian function and show retarded
development of their mammary glands (Hu et al. 2004, Walters 2015). In addition, cell-
selective AR knockout models with Cre/loxP technology have revealed tissue- and cell-
specific functions of AR in both male and female animals (Zhou 2010, De Gendt &
Verhoeven 2012). It is well known that androgens act through the AR. The AR is a ligand-
dependent TF which is a member of the nuclear receptor (NR) superfamily; in humans, this
superfamily contains 48 known NRs (Gelmann 2002). Androgen binding initiates sequential
conformation changes in the AR and its subsequent transfer to the nucleus, where it binds
to specific androgen response elements (AREs) on the regulatory regions of its target genes.
In this way, the AR conveys the message of androgens directly to the level of genetic
programs (Gao et al. 2005b, Makkonen et al. 2009, Green et al. 2012, Sampson et al. 2013).
2.2.1 Protein structure
The AR gene was localized to the human X chromosome in 1981 by Migeon and co-workers
and it was found to consist of 8 exons as shown in Figure 2 (Migeon et al. 1981). The AR
contains 919 amino acid residues, although the number of amino acid residues can vary
between  individuals  due  to  the  presence  of  polymorphic  polyglutamine  and  polyglycine
stretches (Sleddens et al. 1993, Palazzolo et al. 2008). Two AR isoforms, the full length
receptor and an amino-terminally truncated form, have been identified in normal human
tissues, although the functional significance of the smaller AR is not established (Trapman
et al. 1988, Wilson & McPhaul 1996, Dehm & Tindall 2011).
AR  is  structurally  and  functionally  related  to  the  class  I  steroid  receptors  (SR),  which
include AR, glucocorticoid receptor (GR), progesterone receptor (PR), mineralocorticoid
receptor and estrogen receptor (ER) (Aranda & Pascual 2001, Huang et al. 2010). SRs
structures can be roughly divided into four distinct domains: N-terminal-activating domain
9(NTD), DNA-binding domain (DBD), hinge region and C-terminal ligand-binding domain
(LBD) as shown in Figure 2 (Tan et al. 2015).
Figure 2. Genomic organization of the androgen receptor (AR) gene and the functional domain
structure of the AR protein. The AR gene contains eight exons, and it codes for a protein which
is  919  amino  acids  long  consisting  four  major  functional  domains:  N-terminal  domain  (NTD),
DNA-binding domain (DBD), hinge region (H) and ligand-binding domain (LBD). In addition, the
main functions of the domains and the SUMOylation lysines (K) are shown. (Modified from Tan
et al 2015).
The NTD is the most variable domain within the SRs and the AR NTD has little amino
acid sequence homology to the other SRs. Thus, the NTD can partially be the reason for the
specificity  of  the  receptor  response.  The  NTD  interacts  with  C-terminal  LBD  in  a  ligand-
dependent  manner  and this  stabilizes  the  transcriptionally  active  AR dimer  complex;  this
interaction is required to obtain the full transcriptional potential of AR (Zhou et al. 1995,
Ikonen et al. 1997, Centenera et al. 2008). Thus, the NTD is an important transcriptional
regulatory region of the protein and it is a site for the interaction between the AR and its
many coregulators (Bevan et al. 1999, Alen et al. 1999). The NTD contains an activation
function (AF) 1, which is hormone-independent, and in the absence of LBD, AF-1 becomes
constitutively active (McEwan 2004). Additionally, the NTD contains many sites for PTMs
(e.g. phosphorylation, SUMOylation, ubiquitylation) (Poukka et al. 2000, Gioeli et al. 2002,
Kaikkonen et al. 2009). The AR NTD includes 60% of the protein´s amino acids (558
residues) and it contains the previously mentioned polyglutamine and polyglycine repeat
sequences.  Individuals  may  therefore  have  a  difference  in  the  length  of  their  NTD.
Normally the numbers of polyglutamine repeats range from 8 to 31; it has been reported
that repeats with lengths over 40 can cause spinal and bulbar muscular atrophy (Kennedy´s
disease) (La Spada et al. 1991).
The DBD is the best conserved region in the NRs and the structure of the DBD was first
published in 1991 (Luisi et al. 1991, Helsen et al. 2012).  The DBD is formed by two
structurally  and functionally  different  zinc  fingers,  one of  which makes  contacts  with  the
ARE and another creates a dimerization interface with another AR molecule (Shaffer et al.
2004, Jakob et al. 2007). Interestingly, only a few amino acids in the first zinc finger DNA
recognition helix are responsible for the sequence-specific DNA contacts. The non-
conserved, flexible hinge region, which contains the main nuclear localization signal is
located between the DBD and the LBD.
The AR LBD is folded into 12 ?-helices, which form a ligand-binding pocket as in other
members of the SR family. This pocket consists of 18 amino acid residues, which are critical
for the receptor’s interaction with an androgen (Matias et al. 2000, Sack et al. 2001). Deletion
of LBD leads to a constitutively active AR (Jenster et al. 1991).
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2.2.2 Androgen receptor-mediated transcription
The AR is expressed at some level in almost all tissues, although mostly in prostate,
adrenal gland and epididymis.  In the absence of ligand, AR exists mainly in the cytosol in
a multiprotein complex with heat shock proteins (e.g. heat shock protein 90) and
immunophilin chaperones (e.g. p23, FKBP51, FKBP52) as shown in Figure 3 (Prescott &
Coetzee 2006, Echeverria & Picard 2010). Testosterone and its more active metabolite, DHT,
are  the  main  endogenous  AR  ligands.  Testosterone  is  primarily  synthesized  from
cholesterol in Leydig cells in the testes, but small amounts are also synthesized in adrenal
cortex, liver and in the ovaries in women. Circulating testosterone is bound to carrier
proteins (sex hormone-binding globulin or albumin), which protect it from degradation and
“buffer” the amount of biologically active testosterone. Testosterone diffuses from the
blood into cells but for example in prostate cells, it can be converted into DHT by 5?-
reductase. Ligand binding to the receptor in the cytoplasm triggers conformational changes
in  the  LBD  such  that  the  NTD  and  the  LBD  of  the  receptor  interact.  This  conformational
change  releases  AR  from  its  protein  complex,  leading  to  receptor  homodimerization  and
nuclear translocation (Figure 3) (McEwan 2004, Palvimo 2012). The AR moves into the
nucleus very rapidly; it can be detected on chromatin within a few minutes after androgen
exposure with maximal binding present at two hours (Massie et al. 2011). When there is no
ligand present, there is very little AR binding to chromatin. In the nucleus, the dimerized
AR binds to specific DNA sequences, AREs, in the proximal promoter and/or distal
enhancer elements of its target genes, which are often occupied by pioneer factors, such as
FOXA1 in the prostate (Sahu et al. 2011, Pihlajamaa et al. 2014). This initiates the formation
of a protein complex, which finally leads to the activation or repression of AR target genes.
In some cells, such as prostate cells, the AR may interact directly with general transcription
machinery factors (TFIIB, TFIIH), which are associated with RNA polymerase II (Roeder
1996, Lee & Chang 2003, Lavery & McEwan 2008, Roy & Singer 2015). In addition to the AR
and the general transcription machinery, the protein complex includes DNA-binding
collaborating TFs and non-DNA binding co-regulatory factors, such as Mediator complex
(Shang et al. 2002, Wang et al. 2007). The function of the AR collaborating TFs and
coregulators  will  be  discussed  in  greater  detail  in  the  next  chapters.  In  this  way,  AR-
directed transcription leads to altered expression of the androgen responsive genes (Figure
3). These AR-dependent gene products are involved in several crucial cellular functions,
including cell survival, cell proliferation, apoptosis and lipid and sterol metabolism
(Lamont & Tindall 2010).
Over the last decade, a new powerful technique, chromatin immunoprecipitation (ChIP)
combined with massively parallel DNA sequencing (ChIP-seq), has advanced our
understanding of gene regulation (this technique is described in more detail in materials
and methods). Thus, the old, traditional model of SR binding to the proximal promoter of
target genes has been revised. ChIP-seq studies have revealed tens of thousands of AR
binding sites (ARBs) across the human genome (Sahu et al. 2011, Massie et al. 2011, Chng et
al. 2012). Since AR is mainly found in intergenic and intronic regions, it is clear that AR can
regulate its target genes from a distance, far away from the boundaries of a classical
promoter region (Wang et al. 2009b, Robinson et al. 2011, Jin et al. 2013). Thus AR binds to
distal enhancers and communicates with promoters through chromatin looping (Wang et
al. 2007). Additionally, AR binding has been demonstrated in a variety of PCa cell lines to
be distinct and thus, to exhibit cell type specific features. Similarly in vivo ChIP-seq
profiling of ARBs in prostate, epididymis and kidney have found evidence for only a minor
overlap, highlighting tissue-specificity of binding sites (Pihlajamaa et al. 2014). Taken
together, it seems that collaborating TFs, coregulators, and pioneer factors ultimately
determine  the  AR  binding  site  selection  on  chromatin  and  this  then  occurs  in  a  cell-  and
tissue-specific manner.
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Figure 3. Androgen receptor (AR) signaling in prostate cells. After synthesis, testosterone is
transported to target tissue bound to serum sex hormone-binding globulin (SHBG) where it
becomes converted into dihydotestosterone (DHT) by 5?-reductase. DHT binding induces a
conformational change in the AR, which loses its chaperone heat shock proteins (HSP),
dimerizes, and translocates to the nucleus. There it binds to the androgen-response element
(ARE)  under  the  guidance  of  pioneer  factors.  The  AR  recruits  basal  transcription  machinery,
Mediator complex (MED), coregulators and collaborating transcription factors, which are needed
for gene transcription. (Modified from Tan et al 2015).
ChIP-seq studies have also revealed more details about ARE. Motif analyses of receptor-
bound DNA sequences have confirmed that the AR binds mainly to two types of elements:
1) the classical,  canonical ARE which contains two 6-pair inverted half-sites with a three
nucleotide spacer (5´-AGAACAnnnTGTACC-3´) (Roche et al. 1992, Mangelsdorf et al.
1995). 2) Selective ARE with only a well-conserved 5´hexamer and usually head-to-head or
head-to-tail position (Verrijdt et al. 2003, Denayer et al. 2010, Sahu et al. 2014). The latter
ARE is recognized by an AR second zinc finger and it seems that the selective ARE has a
relaxed rather than an increased stringency of sequence.  Similarly, the best characterized
androgen-regulated genes are not regulated by perfect AREs. The classical ARE is also
recognized by other SR, due to highly conserved DBD in these proteins,  and for instance,
AR  and  GR  genome-wide  binding  sites  overlap  significantly  (Sahu  et  al.  2011).   Thus,  as
mentioned above, the surrounding binding sites, like pioneer factors binding sites,
ultimately govern the final activation of AR target genes.
2.2.3 Pioneer factors
Pioneer  factors  are  a  specific  class  of  TFs,  which  are  able  to  access  their  own  DNA
recognition motifs even in transcriptionally silent, compact chromatin, this allows them to
undertake high-affinity DNA binding (Cirillo et al. 2002, Zaret & Carroll 2011). They are
thought to displace nucleosomes to loosen chromatin and bind to the genome for a period
prior to the binding of other factors. Thus, they enable the binding of other TFs that cannot
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access their target sequence on their own in compacted chromatin. Pioneer factors have
been studied with in vivo footprinting assays  to  obtain  clues  to  the  ways that  TFs  bind to
silent chromatin prior to target gene activation. FOXA1 and GATA were the first pioneer
factors to be identified during liver development, where they have especially crucial roles
(Holtzinger & Evans 2005, Lee et al. 2005). In addition to the FOXA family and GATA-
binding factors, multiple proteins have been shown to possess pioneer factor properties
(e.g. TLE-factors, PU.1) (Sekiya & Zaret 2007). Recent ChIP-seq studies have revealed that
the motifs of pioneer factors are enriched within NR binding sites. In particular, FOX and
GATA  motifs  were  enriched  within  AR  and  ER  binding  sites.  Pioneer  factors  have  been
shown to have a role in stem cells and hormonal regulation, especially in hormone-
dependent cancers (Jozwik & Carroll 2012). Reprogramming cells to pluripotency requires
the  opening  of  silent  chromatin  and  the  revelation  of  target  sites.  Future  studies  with
pluripotency factors (e.g. Oct4, Sox2 and c-Myc) could confirm whether or not they possess
pioneer factor activities. The function of pioneer factors is influenced by PTMs, micro RNAs
and mutations (Belaguli et al. 2012).
2.2.3.1. FOXA1
FOXA  is  one  of  the  19  subfamilies  of  the  large  FOX  superfamily  of  TFs  in  humans  (at
present with names ranging from FOXA to FOXS); FOXA contains three members (FOXA1-
3) (Hannenhalli & Kaestner 2009, Lam et al. 2013). All FOX proteins have forkhead DBD
and most of them bind to DNA as monomers (Lai et al. 1990, Lehmann et al. 2003). The
FOXA1 (also hepatocyte nuclear factor 3?, HNF-3?) gene is located on human chromosome
14 and it contains 2 exons; the gene codes for a protein of 472 amino acid residues (Figure 4)
(Mincheva et al. 1997). As with other members of the family, the DBD of FOXA1 has a
winged helix structure similar to that of linker histone H1 and it is thus able to replace H1
on chromatin, generating a more open chromatin (Clark et al. 1993). FOXA1 binds as a
monomer to  one face  of  the  DNA helix,  allowing other  proteins  to  be  bound to  the  other
site. The DBD is flanked by nuclear localization signal sequences, which ensure the nuclear
targeting and delivery of the protein (Kaestner 2000). Additionally, FOXA1 contains four
transcriptional activation domains, two of which (IV and V) are located in the N-terminal
region  and  the  other  two  (II  and  III)  in  the  C-terminal  region  of  the  protein  (Figure  4)
(Friedman & Kaestner 2006).
Figure 4. Schematic functional domain structure of FOXA1 showing the transcriptional activation
domains, DNA-binding domain (DBD) and SUMOylation lysines (K). (Modified from Costa et al.
2001).
FOXAs are pioneer TFs that play vital roles in the development of many organs (Gao et
al. 2005a, Hannenhalli & Kaestner 2009). FOXA1 was originally identified as a regulator of
liver-specific gene transcription and its importance during development has been
demonstrated in many knockout mice models (Bernardo & Keri 2012). Foxa1 null mice
survive through embryogenesis, but die postnatally due to severe hypoglycemia and
dehydration (Kaestner et al. 1999, Shih et al. 1999). Thus, FOXA1 has an important role in
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glucose homeostasis and pancreatic islet function. Furthermore, there is evidence that the
FOXA1  is  important  for  lung  development  and  in  the  development  of  the  breast  and
prostate during pubertal morphogenesis (Besnard et al. 2005, Gao et al. 2005a, Bernardo et
al. 2010). Similarly to AR, FOXA1 is highly expressed in prostate tissue and it is important
in prostate regulation from the start of development throughout adulthood (Gao et al. 2003,
Gao et al. 2005a). This is largely due to the ability of FOXA1 to control the AR-modulated
transcription of prostatic genes.
FOXA proteins are pioneer factors for several NRs, and lately high-throughput
technologies have provided a wider view of this co-operation (Gao et al. 2003, Zhang et al.
2005, Yu et al. 2005, Laganiere et al. 2005, Carroll et al. 2006, Hurtado et al. 2011). Pioneer
factors determine NR target gene expression as ChIP-seq analysis has revealed that their
DNA  sequence  motifs  are  enriched  within  NR  binding  sites.  However,  FOXA1  is  not  a
ubiquitous pioneer factor, but shows a degree of tissue specificity in its function
(Pihlajamaa et al. 2014). FOXA1 is a known pioneer factor for AR and it facilitates AR-
mediated gene activation, but also functions in AR-mediated gene repression (Gao et al.
2003, Lupien et al. 2008). The DBD of the AR interacts with the forkhead domain of the
FOXA1, which was the first detected at the promoter of the androgen-regulated genes, rat
probasin and human prostate-specific antigen (PSA; encoded by KLK3) (Gao et al. 2003).
Recent ChIP-seq studies have revealed that the role of the FOXA1 in AR regulation is
versatile and depends not only on genes and androgens but also on the equilibrium
between these two factors (Jin et al. 2014). FOXA1 binds to substantially more genomic
regions than AR and although the majority of ARBs co-occupy with FOXA1, the majority of
FOXA1 binding sites are not co-occupied by the AR, evidence that FOXA1 is not sufficient
to recruit AR (Lupien et al. 2008, Sahu et al. 2011). Similarly, FOXA1 silencing in PCa cells
led to a global redistribution of ARBs, creating new ARBs and initiating new transcriptional
programs (Sahu 2011). In the absence of FOXA1, AR binds to more specific ARE motifs
instead of the forkhead binding site (Jin et al. 2014). Thus FOXA1 can induce AR binding in
some chromatin regions, block the binding in other regions and some cases AR binding is
independent of FOXA1. Taken together, it seems clear that FOXA1 participates in AR
target-gene  recognition,  but  this  regulation  seems  to  be  dependent  on  the  presence  of
additional coregulators. FOXA1 is thus necessary for AR function, playing a critical role in
prostate development and therefore also in PCa, where it has a role in early stage of cancer
through to CRPC. This will be discussed in greater detail in chapter 2.3.2.
2.2.4 Androgen receptor  collaborating transcription factors
Recent genome-wide ChIP-seq studies have revealed a new aspect of AR binding and
highlighted also the role of coregulators and collaborating TFs in AR-mediated
transcription. In particular, the Encyclopedia of DNA Elements (ENCODE) Consortium has
provided comprehensive ChIP-seq datasets (http://genome.ucsc.edu/ENCODE/). With
these  and  other  studies,  predicted  de  novo  co-occupancy  between  AR  and  several
collaborating TFs has been confirmed. Multiple TFs have been shown to interact physically
and functionally with AR (AP-1, ERG, HOXB13, FOXA1, GATA2, Oct1, RAR, ETS1, HNF-
??) (Heemers & Tindall 2007). Those AR collaborating TFs, which were discovered during
this thesis study, will be discussed in greater detail in the next chapters.
2.2.4.1 AP-1
Activator protein-1 (AP-1) transcription factor family consists of either homo- or
heterodimer members belonging to Jun (c-Jun, JunB and JunD), Fos (c-Fos, FosB, Fra-1 and
Fra-2) and the activating transcription factor (ATF) (ATFa, ATF2, LRF1/ATF3, ATF4, JDP-1
and JDP-2) families (Angel & Karin 1991, Jochum et al. 2001, Hess et al. 2004). These AP-1
complex proteins have the DBD combined with the basic leucine zipper domain (bZIP),
which enables protein dimerization (Glover & Harrison 1995). Dimerization is essential for
DNA-binding and for forming of transcriptionally active complexes. Jun proteins can both
homo- and heterodimerize, whereas Fos proteins can only heterodimerize. Heterodimers
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between Fos and Jun proteins form the most stable complexes, but there are differences in
individual Jun and Fos proteins´ binding affinities to DNA (Ryseck & Bravo 1991, van Dam
& Castellazzi 2001, Pernus & Langowski 2015).
AP-1 activity is regulated by environmental changes (cytokines, growth factors, stress
signals  and  infections).  Activated  AP-1  binds  to  its  target  gene´s  AP-1  binding  site  (5'-
TGAG/CTCA-3'),  which is  also  known as the TPA-responsive element (Angel et al. 1987).
Due to the great number of AP-1 dimers, AP-1 can act as a positive or negative
transcriptional regulator, depending on the cell type, its composition and the target gene
(Hess et al. 2004). Therefore, AP-1 has a role in a large variety of biological processes
including cell differentiation, proliferation, apoptosis and oncogenic transformation
(Jochum et al. 2001, Eferl & Wagner 2003, Zenz et al. 2008).
AP-1  has  been  observed  to  undergo  cross-talk  with  many  TFs,  including  SRs
(Shemshedini et al. 1991, Bamberger et al. 1999, Kushner et al. 2000, Karin & Chang 2001).
Different AP-1 subunits have been shown to work with AR but there are quite controversial
results about the role of the subunits either as activators or repressors of the AR (Sato et al.
1997, Wise et al. 1998, Bubulya et al. 2001, Yuan et al. 2010). In addition, in some cases, AP-1
competes with AR for coregulators that are present in limited amounts within the cell.
Furthermore, the role of the AP-1 in PCa has been investigated and its transcriptional
activity seems to affect development and progression of PCa.  AP-1 subunits have been
associated  with  a  more  aggressive  clinical  outcome  and  both  JunB  and  Fos  are
overexpressed in primary tumors and downregulated in metastatic samples (Chandran et
al. 2007, Thomsen et al. 2015).  However, most of the PCa studies have focused on
examining the expression levels in tissue samples and the molecular mechanism for the role
of AP-1 in PCa is unclear.
2.2.4.2 C/EBP
CCAAT/enhancer-binding proteins (C/EBPs) are a family of TFs, which bind to regulatory
regions of their target genes at a CCAAT box sequence motif (Lekstrom-Himes &
Xanthopoulos 1998). The family contains six members (C/EBP?, -?, -?, -?, -? and -?) and all
of them share a highly conserved C-terminus, which includes basic DBD and bZIP (Cao et
al. 1991, Ramji & Foka 2002). This bZIP enables homo- and hetero dimer complex formation
with each other, similarly to the situation in AP-1 proteins (Vinson et al. 1993). All the
C/EBPs have diverse functions as activators or repressors depending on their structure (e.g.
C/EBP? and -? lack activation domains and function as inhibitors) (Cao et al. 1991, Cooper
et al. 1995). C/EBPs regulate growth and differentiation of several tissues, immune and
inflammatory responses and various diseases (Ramji & Foka 2002).
C/EBP? and  C/EBP? have  both  been  shown  to  undergo  cross-talk  with  AR  and  they
seem to have a role in PCa. They have multiple isoforms and are known to be key
regulators of proliferation and differentiation in multiple tissues (Umek et al. 1991,
Robinson et al. 1998). C/EBP? is expressed in prostate epithelial cells and it inhibits cell
proliferation in the prostate (Chattopadhyay et al. 2006, Yin et al. 2006, Zhang et al. 2008b).
This inhibition is at least partly due to C/EBP? binding to AR, which recruits corepressor
activity to the AR target genes (Chattopadhyay et al. 2006, Zhang et al. 2010). Interestingly,
C/EBP? expression is directly suppressed through its promoter regulation by AR (Barakat
et  al.  2015).  C/EBP? has  a  role  in  PCa:  in  addition  to  acting  with the AR, it regulates the
expression of steroidogenic genes (steroidogenic acute regulatory protein) and the
responsiveness to steroid hormones (Christenson et al. 1999, Mantena et al. 2006, Jia et al.
2008). In castration-resistant prostate cancer (CRPC) samples, C/EBP? expression is
significantly elevated (Oncomine database, Grasso et al. 2012).
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2.2.4.3 ERG
ETS-related gene (ERG) is one of the 28 erythroblast transformation-specific (ETS) family
TFs identified in humans (Leprince et al. 1983, Adamo & Ladomery 2015). These ETS TFs
have a specific conserved DBD, which recognizes a DNA sequence with a GGA(A/T) core,
but surrounding sequence preference vary in the ETS family (Karim et al. 1990, Donaldson
et al. 1996). In addition, ERG contains a protein-protein interaction pointed domain, which
helps heterodimerization with ETS family members and other factors, such as AR
(Basuyaux et al. 1997).  ERG has been shown to bind DNA with AP-1 complex and in this
way it can facilitate the access of the transcriptional machinery to the DNA (Verger et al.
2001). The ETS family members can act as transcriptional activators or repressors
(Gutierrez-Hartmann et al. 2007). Generally they regulate widely different biological
processes, such as cell proliferation, cell cycle and apoptosis (Gutierrez-Hartmann et al.
2007).  Thus, they are associated with different types of cancers. ERG is a well known
oncogene in multiple cancer types (for example, leukemia, PCa) and it is involved in
regulating the cellular architecture, cell migration, cell permeability, angiogenesis,
inflammation and apoptosis (Birdsey et al. 2008, Carver et al. 2009, Birdsey et al. 2012,
Dryden et al. 2012).
ERG is involved in PCa through fusion to an androgen-regulated transmembrane serine
protease 2 (TMPRSS2)  promoter  (Tomlins  et  al.  2005).  This  fusion  occurs  early  in  the
development of PCa. It seems to be aided by androgen exposure: androgen stimulation
leads to co-recruitment of ligand-bound AR and topoisomerase II? to TMPRSS2 and ERG
regulatory regions, followed by the generation of double strand breaks and finally
rearrangements (chromosomal translocation or more often deletion of intergenic region
between genes) (Tu et al. 2007, Haffner et al. 2010). The promoter region of TMPRSS2
becomes fused to the coding region of ERG:  usually  the  exon  1  of TMPRSS2 and whole
coding region of ERG (exon 4-11) are fused together, but different fusion types are possible
and affect the aggressivity of PCa (Tomlins et al. 2011).  Due to an ARE in the TMPRSS2
regulatory region, ERG becomes androgen sensitive and overexpressed in the presence of
androgens. This overexpression induces ERG´s target genes, which promote cell invasion
(through FZD4 gene) and metastasis, in addition to the repression of prostate epithelium-
specific gene (KLK3) (Sun et al. 2008, Gupta et al. 2010). Prostate epithelia do not normally
express  ERG,  but  the  gene fusion causes  ERG overexpression in  malignant  PCa,  with  the
gene fusion being detected in approximately half of the primary prostate tumors (Tomlins
et al. 2011). Furthermore, the TMPRSS2-ERG fusion gene is associated with a more
aggressive PCa phenotype with shorter survival times (Hagglof et al. 2014). Additionally,
recent ChIP-seq studies have confirmed the existence of direct cross-talk between ERG and
AR; their binding sites overlapped significantly in PCa cell lines and PCa tissue (44 %
common binding sites) (Yu et al. 2010). Thus, ERG has a role in regulating AR function and
also  in  this  way  it  is  involved  in  PCa.  Since  ERG  overexpression  is  encountered  in
aggressive PCa and absent in benign prostate tissue, the assay of TMPRSS2-ERG gene
fusions could be a diagnostic tool and therapies based on ERG are being developed
(Brenner et al. 2011, Tomlins et al. 2011, Salami et al. 2013).
2.2.5 AR coregulators
Coregulators are required for AR-mediated transcriptional regulation. AR recruits these
proteins to enhance (coactivators) or reduce (corepressors) transactivation. Whether a
coregulator functions as an activator or a repressor can be TF and cell type specific
(Rosenfeld et al. 2006). In the situation when there are no ligands present, the AR is
complexed with HSPs and transcriptionally silent, for this reason, there are only a few
known AR corepressors. In contrast to collaborating TFs, coregulators do not significantly
alter the basal transcription rate and they bind directly to the TFs or coregulator complexes,
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but they do not bind to DNA or possess any specific DNA binding affinities. Recent
genome-wide  ChIP-seq  studies  have  revealed  a  new  aspect  of  the  role  of  coregulators  in
AR-mediated transcription. Overall, AR has been suggested to have around 200
coregulators and these coregulatory complexes are required for the regulation of the basal
transcription machinery (Heinlein & Chang 2002, Heemers & Tindall 2007). The majority of
these coregulators are able to associate directly to AR.  This is possibly due to sequential
binding and the interaction with different regions of the AR. Additionally, coregulators are
often components of multi-subunit co-regulator complexes possessing a multitude of
enzymatic activities. However, these identified coregulators are able to modulate the
transcription of several other NRs and therefore, the number of truly AR-specific
coregulators is likely to be relatively small. The putative coregulators have versatile
functions and they are generally divided into two families: those which facilitate DNA
occupancy (at the target gene promoter), chromatin remodeling and recruitment of basal
transcription machinery and those which modulate the AR itself.
AR activity largely depends on its ability to come into contact with its binding sites on
chromatin.  When DNA is  tightly  wrapped around histones,  the  AR cannot  gain  access  to
DNA. Chromatin remodeling complexes can alter chromatin structure and unwrap the
histone-DNA complexes to make them more permissive for transcription or it can condense
the chromatin structure and promote gene repression (Li et al. 2007).  Thus, many of the AR
coregulators are components of the chromatin remodeling complex (Clapier & Cairns 2009).
AR-interacting protein (ARIP) 4, is a member of the SNF2-like family, which is known for
its chromatin remodeling properties. ARIP4 contains the Snf2-domain and is an active
DNA-dependent ATPase able to generate superhelical torsion on linear DNA fragments.
ARIP4 interacts with AR (zinc-finger region) and modulates AR-mediated transcription
(Rouleau et al. 2002). In addition, coregulators can covalently modify N-terminal histone
residues (acetylate, phosphorylate, ubiquitylate, methylate). Specific combinations of
covalent histone modifications can loosen or tighten the DNA-histone interactions (Mellor
2006, Li et al. 2007). This creates a complex “histone code” for the regulation of gene
expression. NR´s coregulators mainly (de)acetylate or (de)methylate histones. Histone
acetylase (HAT) activity is generally associated with transcriptional activation, because the
positive charge present on the histone tails disrupts chromatin structure and prevents
nucleosome-nucleosome interactions (Strahl & Allis 2000). Steroid receptor coactivator 1
and 3 (members of p160/SRC gene family) and cAMP response element binding protein
(CBP)/p300 are recognized AR-interacting HATs (Alen et al. 1999). Similarly, many histone
deacetylases (HDAC) interact with AR. They remove the acetyl group, which leads to the
formation of a condensed nucleosomal structure and silencing of transcriptional activity. In
addition, methyltransferases and demethylases are known to interact with AR (Yamane et
al. 2006). Mediator, a multi-subunit complex, is also important in AR transcriptional
activation. Unlike the enzymatically active HATs and HDACs, it seems to function as a
bridge between the receptor, basal transcription machinery and RNA polymerase II (Figure
3)(Taatjes 2010).
Other coregulators can modulate appropriate folding, ligand binding, NH2/COOH-
terminal interaction, stability or correct subcellular location of the AR (Heemers & Tindall
2007). These coregulators are often recruited to the hinge region or the AR NTD (especially
in AF-1). AF-1 can bind to LxxLL motif (where L is leucine and x any amino acid), which is
commonly present in coregulators (van de Wijngaart et al. 2012). The AR-associated protein
of 70 kDa is an example of this category of coregulators, it can stabilize the ligand-bound
receptor; there is also filamin that facilitates the translocation of the ligand bound receptor
to the nucleus. In addition to influencing AR-dependent transcription, AR´s coregulators,
such as  PIAS1,  can promote  AR´s  PTMs as  mentioned earlier,  which in  turn can regulate
AR´s transcriptional activity (Kotaja et al. 2000, Poukka et al. 2000). Recent genome-wide
studies  suggest  that  PIAS1  could  function  as  a  genuine  and  chromatin-bound  AR
collaborating TF, regulating AR target genes in PCa cells (Toropainen et al. 2015).
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2.3 PROSTATE CANCER
In  the  developed  countries  like  Finland,  PCa  is  one  of  the  most  frequently  diagnosed
cancers  and  one  of  the  most  common  causes  of  death  from  cancer  in  men
(www.cancerresearchuk.org, www.cancerregistry.fi). The prostate gland is located below
the  bladder  and  it  surrounds  the  urethra.  Its  main  function  is  to  produce  fluid  which
protects and nourishes sperm. PCa is common in elderly men: the tumor normally grows
very slowly and the patient can be asymptomatic for decades. Thus, age is the most
significant risk factor for PCa combined with environmental, physiological (obesity) and
molecular influences (Shen & Abate-Shen 2010). In addition to the gene expression changes
involved in inflammation, oxidative stress and cellular senescence affect PCa risk (Begley et
al. 2005, Bethel et al. 2009). There are no common symptoms for PCa and elderly men can
also have the non-life-threatening benign prostate hyperplasia, a factor which makes PCa
detection demanding and difficult (Schroder et al. 2014). Prostatic secretions contain PSA
and a high serum concentration of this protein is the most common PCa screening test, even
though a high amount of PSA can be also present in benign prostatic hyperplasia (Wolf et
al. 2010, Delahunt et al. 2012). Unlike the situation in benign overgrowth, PCa cells
eventually break out of the prostate and metastasize to other tissues, particularly to bones
and lymph nodes, but also to other organs. PCa is a very heterogenic cancer and it would
be a major advance if it were possible to differentiate aggressive cancers from those which
do not need active treatment and only have to be followed. The need for improved
diagnostic techniques in addition to PSA screening and Gleason scoring has not changed
much in 50 years (Mellinger et al. 1967), even recent publications have highlighted the need
for better prognostic biomarkers (Epstein 2010). Specific, targeted treatment is also
important if one wishes to maintain the patient’s quality of life: Current PCa treatments
have serious side-effects like skeletal complications, metabolic and cardiovascular
complications, sexual dysfunction, hot flashes, periodontal disease, deterioration in
cognition, and mood disorders (Alibhai et al. 2006).
Recently, genome-wide approaches have identified and confirmed common genetic
alterations in PCa (Barbieri et al. 2013, Mills 2014). The major pathways affecting
tumorigenesis are the phosphoinositide-3-kinase (PI3K) and the mitogen activated protein
kinase  pathways  and  AR  signaling.   PI3K  signaling  is  important  for  cell  growth  and
survival pathways and it is up-regulated in between 30 % to 50 % of PCas. PTEN, a tumor
suppressor gene, decreases AR transcriptional activity by reducing the rate of AR nuclear
translocation and AR protein stability. Furthermore, PTEN is a negative regulator of PI3K-
dependent signaling and thus loss of PTEN,  which  occurs  in  40%  of  primary  tumors,  is
associated with poor prognosis. Notably, changes in AR-mediated gene regulation remain
important in the development and progression of PCa. This includes the gene fusion of
TMPRSS2-ERG (see 2.2.4.3), the AR target gene NKX3.1, a tumor suppressor, cross-talk
with MYC oncogene, and changes in AR function, which will be discussed in greater detail
in the next chapter.
2.3.1 Role of androgen receptor in prostate cancer
Already in 1940s, it was demonstrated that androgens make a crucial contribution in the
development and progression of PCa, and androgen signaling has a key role at all stages of
PCa (Huggins & Hodges 2002). Due to the dependency of the cancer cells on androgens, the
first-line treatment for PCa is impairment of AR activity by androgen deprivation. This can
be  achieved  by  lowering  the  levels  of  circulating  testosterone  (either  surgical  or  chemical
castration) or with antiandrogens (e.g. flutamide and bicalutamide) (Haendler & Cleve
2012). Antiandrogens compete with testosterone for binding to LBD of AR and in this way
they antagonize AR activity. These strategies are typically effective for some time, but often
PCa  cells  will  develop  resistance  to  these  treatments  and  progress  to  hormonal
manipulation resistant cancer, CRPC. Interestingly, still at this stage, AR signaling remains
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active and crucial for tumor growth due to several alterations in AR function (Chen et al.
2008, Wang et al. 2009b, Knudsen & Kelly 2011, Ferraldeschi et al. 2015). PCa cells can have
increased amounts of AR due to overexpression (80 % of CRPCs have a marked increase in
AR mRNA and protein) or AR gene amplification (30 % of CRPC tumors) (Visakorpi et al.
1995, Koivisto et al. 1997, Linja et al. 2001). Additionally, AR function can be changed due
to mutations: more than 100 somatic mutations in the AR have been described. Mutations
in  the  hinge  region  or  LBD  can  increase  AR  activity  or  relax  the  ligand  specificity  of  the
receptor e.g. leading to its activation by other steroid hormones (Veldscholte et al. 1990,
Balbas et al. 2013). Furthermore, due to these mutations, the effect of some antagonists can
be switched so that they exert agonist-like activity. For example, a recently discovered
missense mutation in the LBD (F876L) was found to convert two second-generation
antiandrogens, enzalutamide and arabiterone acetate, into AR agonists (Korpal et al. 2013).
Moreover,  alternative  AR  splicing  (often  lack  of  the  LBD),  can  cause  expression  of
constitutively active AR splice variants (Hu et al. 2009, Hu et al. 2012). The AR splice
variant 7, lacking the LBD, is the most abundant and best characterized splice variant
detected in CRPC (Antonarakis et al. 2014). Similarly, amplified levels of coactivators can
keep AR active, and ChIP-seq studies have shown that pioneer factors of AR (FOXA1 and
GATA2) and a subset of AR coactivators are frequently over-expressed in PCa (Gregory et
al. 2001, Tomlins et al. 2005, Wang et al. 2007). The aforementioned components of the
SUMOylation pathway, which function as AR coregulators, have been shown to contribute
to the proliferation of PCa cells. For instance, PIAS1 expression has been associated with
cancer initiation and high PIAS1 levels predict shorter relapse-free survival (Puhr et al.
2015). Due to the similarity of all SRs, it could be possible that other SRs could also bypass
an AR pathway blockage. Recent genome-wide ChIP-seq studies have found evidence for
an interplay between AR and GR pathways in PCa cells. Glucocorticoids are widely used in
the treatment of CRPC, and thus it could be possible that active GR signaling may also
regulate AR signaling under androgen-deprived conditions in PCa (Sahu et al. 2013, Isikbay
et al. 2014). Furthermore, PCa cells can remain AR active by locally producing themselves
androgens from cholesterol (Montgomery et al. 2008).
Experiments have been conducted to determine which of the AR-regulated genes are
important for the progression of PCa and the role of AR in PCa has been studied in a
variety of models. There are several mouse xenograft models, as well as transgenic and
knockout mice, that have been used for models of PCa (Shen & Abate-Shen 2010). These
models have their limitations (e.g. xenograft mice cannot trigger endogenous immune
responses), but they have yielded a vast amount of information about the role of AR and
the molecular mechanisms involved in PCa. Similarly several PCa cell lines have been
generated from PCa metastases, such as LNCaP (lymph node), VCaP (vertebral) and PC-3
(bone).  The  most  widely  used  model,  LNCaP,  has  a  missense  mutation  in  the  AR  LBD
(amino acid 877), which enlarges the ligand binding capacity (Veldscholte et al. 1992). VCaP
cells, in turn, have AR gene amplification and overexpress the AR. Additionally, VCaP cells
have TMPRSS2-ERG gene fusion, and in this respect they are a very useful model for PCa
(Korenchuk et al. 2001, Liu et al. 2008). During the last decade, new genome-wide studies,
such as microarray and ChIP-seq, have revealed much novel information about androgen-
regulated genes. For instance, microarray studies with VCaP cells have identified over one
thousand androgen-regulated genes, many of which have unknown functions (Toropainen
et al. 2015). More robust expression analyses in human prostate tumors are necessary to
delineate the associations between AR target genes with patient outcomes and anti-
androgen treatment response.
There is no long-term, curative treatment for CRPC, but continuous basic research into
PCa biology has led to the availability of new treatments that have improved outcomes for
CRPC patients (De Maeseneer et al. 2015, Santio et al. 2015, Ferraldeschi et al. 2015). These
treatments include new hormonal therapies that target androgen biosynthesis (e.g.
abiraterone acetate) or the AR directly (e.g. enzalutamide) (Attard et al. 2009, Tran et al.
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2009, Higano et al. 2015). Arabiterone acetate inhibits androgen synthesis in both the
adrenal gland and the cancer cells. Arabiterone acetate is an irreversible CYP17A1 inhibitor
and it blocks the synthesis of androgens from their C21 steroid precursor. Additionally,
arabiterone acetate can act as an antiandrogen (Li et al. 2015). Enzalutamide (MDV3100), a
second-generation antiandrogen, prevents AR function at many levels: it binds to AR with
higher affinity than previous antiandrogens and reduces AR localization to the nucleus,
and  also  inhibits  AR  binding  to  DNA  and  its  co-operation  with  coregulators  (Tran  et  al.
2009). The success of enzalutamide has led to an increased interest of developing other
novel potent antiandrogens (ODM-201, ARN-509). Nonetheless, both of these new
therapies target the AR LBD and thus are ineffective if the receptor is lacking this domain
(Ware et al. 2014, Antonarakis et al. 2014).  Thus, effective AR NTD focusing drugs are
needed, but their development has proved challenging due to the flexibility of the AR NTD.
There  is  one small  molecule  inhibitor,  EPI-001,  which targets  the  AR NTD and it  inhibits
AR transactivation by disrupting AF-1 function and inhibiting the function of coregulators
(Andersen et al. 2010). In addition to these approaches, new drugs have been aimed at
destabilization of AR by inhibiting HSPs, changing AR coactivators function and blocking
the cross-talk between the AR with other signaling pathways (PI3K/PTEN signaling). In the
future, multi-agent therapies that combine AR-targeted agents with other pathway
inhibitors are likely to be developed. Furthermore, in the future, new techniques (like single
cell/molecule sequencing) may be used in a patient-specific decision-making process and
personalized treatment for PCa (Yadav et al. 2015). This kind of precisely targeted therapy
would ensure minimal side effects and the maximum tumor response.
2.3.2. Role of FOXA1 in prostate cancer
Since  FOXA1 plays  a  crucial  role  in  the  development  of  many organs,  disruption of  its
normal  physiological  function  can  lead  to  the  appearance  of  cancer.  Thus,  FOXA1
expression has been examined in several human cancers, with proposed oncogenic and
tumor suppressive roles (Bernardo & Keri 2012). In particular, FOXA1 has been connected
to the most common cancers, hormonally regulated prostate and breast cancer, where
FOXA1 functions as an AR and ER pioneer factor, respectively (Jozwik & Carroll 2012). A
comparison of FOXA1 binding sites in breast and prostate cancer cells has detected lineage-
specific  profiles  (less  than  40  %  of  shared  binding  sites).  In  ER-positive  breast  cancer
patients, a high FOXA1 level predicts good prognosis (Ross-Innes et al. 2012). In the case of
PCa, FOXA1´s role is not so straightforward, as contrasting evidence has been obtained in
different cohorts of cancer patients. In PCa, the role of FOXA1 in cancer development and
progression seems to be dependent on disease stage, context and treatment history. FOXA1
and  AR  co-expressions  compared  with  the  expression  of  AR  alone  seem  to  cause  poorer
outcomes (Sahu et al. 2011). It has been speculated that FOXA1 can cause increased AR
activity and in this way PCa can circumvent hormonal therapies. In the case of metastatic
human prostate tumors and in patients who have become resistant to hormonal therapy
(CRPC), FOXA1 is overexpressed, a property which appears to be associated with a poor
prognosis (Sahu et al. 2011, Jain et al. 2011, Gerhardt et al. 2012).
The  majority  of  FOXA1  studies  in  PCa  have  focused  on  its  role  in  modulating  AR
transcriptional activity, although FOXA1 can have a role in PCa which does not involve the
AR (Zhang et al. 2011, Yang & Yu 2015). A variety of different mutations in FOXA1 gene
have been identified in PCa tumors (Robinson et al. 2013b). Similarly, single nucleotide
polymorphism within the FOXA1 consensus motif can affect FOXA1´s transcriptional
activity. It  is crucial to gain a thorough understanding of FOXA1´s role in PCa before this
protein can be exploited in combatting hormone receptor-positive diseases.
20
21
3 Aims of the Study
SUMOylation modifies TFs, like SRs, and it can regulate their transcriptional function. This
doctoral thesis aimed to study the role of SUMOylation in the regulation of AR and FOXA1.
Most previous studies of AR SUMOylation have been conducted in cultured cells under
transient ectopic overexpression conditions. In this study, the role of SUMO modification
on AR-dependent transcription was investigated with endogenous AR in PCa cells and in a
genome-wide fashion in cell lines stably expressing wild-type AR (wtAR) or SUMOylation-
deficient AR (AR-2KR). FOXA1 has been shown to interact with a number of other
transcriptional regulators and it has been linked also to the development of prostate and
breast cancers, but surprisingly little is known about the PTMs and their impact on the
function and activity of FOXA1. The new information gathered on the regulation of AR and
FOXA1 function by SUMOylation may also contribute to our understanding of the
development  and progression of  PCa and,  in  the  long run,  possibly  provide us  with  new
targets for combatting this disease.
The specific aims of the study were:
? To determine the effects of cellular signals (androgen or stress treatment) on
endogenous AR SUMOylation in PCa cells.
? To characterize the genome-wide effect of SUMOylation on AR binding to
chromatin in PCa cells.
? To  understand  the  role  of  AR  SUMOylation  in  AR  target  gene  regulation  in  a
genome-wide  fashion  in  PCa  cells  and  to  examine  the  biological  impact  of  this
modification.
? To study the role of SUMOylation in FOXA1 function and in pioneering activity
with the AR.
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4 Materials and Methods
A wide range of molecular and cell biological methods were used in this thesis (Table 1).
Detailed experimental procedures have been described in the original articles I-III.
Table 1. Summary of the methods used in this thesis.
Method Original article
Apoptosis assay II
Bioinformatics II
Cell culture I, II, III
     Generation of cell lines stably expressing AR (PC-3) II
     Generation of isogenic cell lines stably expressing AR (HEK293) I, II
Cell proliferation assay II, III
Chromatin immunoprecipitation (ChIP) I, II, III
ChIP coupled to high-throughput sequencing (ChIP-seq) II
Construction of plasmids and site-directed mutagenesis I, III
Fluorecence recovery after photobleaching (FRAP) I, III
Illumina bead microarray II
Immunoblotting * I, II, III
Immunofluorecence and confocal microscopy I, II, III
Immunoprecipitation I, III
Isolation of RNA I, II, III
Ni2+-Nitrilotriacetic acid pull-down III
Preparation of nuclear matrix I
Quantitative RT-PCR I, II, III
Reporter gene assay ** II, III
RNA interference (RNAi) III
Sequential-chromatin immunoprecipitation (re-ChIP) I
Transient transfection assays I, III
* Detailed protocol in Rytinki et al. 2011 ** Detailed protocol in Makkonen et al. 2011
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4.1 GENOME-WIDE ANALYSIS OF GENE REGULATION
During the last ten years, massively parallel sequencing has become much more widely
accessible; this technique revolutionized the ways in which transcription could be studied
(Cheung & Kraus 2010, Soon et al. 2013). The Sanger sequencing method (capillary
sequencing), in use since 1977, has been replaced with massively parallel sequencing, a
technique which has been commercially available from 2004 (Mardis 2008, Voelkerding et
al. 2009). This has changed research from measuring a few interesting candidate genes to
the possibility of examining at high resolution tens of thousands putative target genes
across the human genome. When this gene expression data is combined with ChIP-seq data
of TFs, it can reveal new activated/inhibited pathways and provide a new perspective of
gene regulatory processes. This present study utilized both the microarray and ChIP-seq
approaches, which will be presented next in more detail. The bioinformatics involved in
both methods will also be described in more detail than in original articles.
4.1.1 Microarray
Work II exploited a microarray (oligonucleotide array) to measure expression levels of large
number  of  genes  simultaneously.  Microarray  technology  was  the  first  practical  technique
for  measuring  genome-wide  transcript  levels  (Schena  et  al.  1995).  It  contains  DNA
oligonucleotides (probes), which are complementary to the sequence of the specific mRNA
molecule (Duggan et al. 1999, Hoheisel 2006). The complementary binding of the labeled
sample to the probes can be measured from the microarray and translated into numerical
values. Although there are several available commercial microarrays, it was decided to
select the Illumina Expression BeadChip, which has gene-specific probes (50 nt) attached to
beads and covers ~47,000 transcripts and known splice variants. One problem encountered
with  the  microarray  approach  can  be  that  it  has  a  limited  detection  range  owing  to  both
background and saturation signals. Furthermore, the microarray is dependent on the
existence of known genomic sequences. Thus, massively parallel sequencing has provided a
new tool for transcriptome research, RNA-sequencing (RNA-seq) (Wang et al. 2009c).
4.1.2 ChIP coupled to massively parallel sequencing
ChIP is an antibody-based technique which can be utilized to study the interactions
between specific proteins and genomic DNA (Solomon & Varshavsky 1985, Solomon et al.
1988, Wacker & Kim 2009). It is often used to detect the binding of TFs to their genomic
targets or to detect specific histone modifications. In the ChIP experiments conducted here,
cells were grown in 10-cm plates in steroid-depleted transfection medium for 72 h and
exposed to vehicle or synthetic androgen (R1881) for 1 h. Then, the DNA and associated
proteins were reversibly and chemically cross-linked by adding 1 % (v/v) formaldehyde to
the medium for 10 min. The cells were rinsed with PBS, collected in hypotonic lysis buffer
and then sonicated to generate 200-500 bp-sized DNA fragments. These DNA fragments
with proteins were immunoprecipitated with specific antibody coupled to protein A
magnetic beads (Millipore) with overnight rotation at 4°C. After washing the beads several
times, antibody-bound chromatin fragments were eluated from the beads by incubation at
65°C for 1 h. The cross-linking was reversed and the proteins were digested with proteinase
K after an overnight incubation at 65°C. Finally,  DNA was purified using the QIAquickTM
PCR  purification  system  (QIAGEN  GmbH).  The  purified  naked  DNA  was  used  in  the
downstream analysis. Traditionally, DNA is used as a template for RT-qPCR (qChIP) to
study  the  specific  gene  of  interest  (as  undertaken  in  original  articles  I,  II  and  III).  In  the
experiments evaluating binding in a genome-wide fashion with ChIP-seq, the harvested
DNA was converted into a ChIP-seq library using NEBNext kit and sequenced (in original
article II) (Kim & Ren 2006, Johnson et al. 2007, Robertson et al. 2007, Park 2009, Furey
2012). The samples were sequenced single-ended using Illumina Hiseq 2000 system, with
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sequencing being performed by repeated cycles of polymerase-mediated nucleotide
extension yielding ~50 bp long reads (~200 million reads/sample). Although there are
several available commercial platforms, most of the ChIP-seq data has been generated with
the Illumina platform, which the ENCODE project has also used (Mardis 2008),
http://genome.ucsc.edu/ENCODE/). Figure 5 summarizes main steps of the ChIP-seq.
Figure 5. The workflow for the analysis of data from chromatin immunoprecipitation followed by
sequencing (ChIP-seq). Blue boxes show steps of ChIP-seq resulting reads in Fastq-format. Red
boxes show steps with command lines resulting Sequence Alignment/Map (SAM) converted to
more condensed Binary Alignmet/Map (BAM). Downstream analyses, shown with purple boxes,
are mostly performed using HOMER.
4.1.3 Bioinformatics
The rapid development in molecular research over the past decades has seen the emergence
of new techniques which can produce tremendous amounts of data e.g. in massively
parallel sequencing, a single instrument run can easily generate hundreds of megabytes to
gigabytes of nucleotide sequences. This has created a demand for new computational
methods to handle this mass of data (Pop & Salzberg 2008, Pepke et al. 2009). For ChIP-seq,
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ENCODE has carried out hundreds of experiments and developed a set of working
standards and guidelines (Landt et al. 2012).
In the case of microarrays, well established protocols for commercially available arrays
are available. The data analysis is therefore much more standardized and straightforward
than for RNA-seq (Garber et al. 2011).  In original work II, the Illumina BeadChIP data were
analyzed within the R environment (http://www.r-project.org/) using the Bioconductor
associated packages (Gentleman et al. 2004). Data were preprocessed (bgAdjust), variance
stabilizing transformed (vst) and robust spline normalized (rsn) with the lumi package (Du
et al. 2008). Differentially expressed genes were analyzed using the Linear Models for the
Microarray Data (limma) package (Smyth 2004)(empirical Bayes statistics with a Benjamini
and Hochberg multiple test correction procedure). Because it was intended to study
androgen-regulated genes, a threshold was set and a gene was considered significantly
changed if it had an adjusted P-value <0.05 and a fold change ? 0.7 or ? 1.4. The R
environment was also used in some downstream analyses, e.g. heat maps were generated
by using heatmap.2 in the R package gplots. In the final downstream analysis, commercial
Ingenuity Pathway Analysis® (IPA,  www.ingenuity.com)  software  was  used  to  identify
biological processes enriched for differentially expressed genes. First, a core analysis was
performed with two distinct lists (androgen-regulated genes in wtAR or AR-2KR
expressing  cells).  The  results  were  then  compared  to  identify  any  distinct  biological
processes that were differentially regulated.
ChIP-seq data in original work II were analyzed mainly with command line tools (Park
2009, Pepke et al. 2009). Command line tools are often used especially in an initial analysis,
but there are also web-based programs available (e.g. Galaxy, www.usegalaxy.org). First,
the Illumina raw reads (~200 million reads) quality was analyzed by FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to find possible abnormal GC
content, excessive clonal amplification, contamination with adapters etc. These poor-quality
reads  were  filtered  out  and  the  reads  were  trimmed  to  50  bp  with  FASTX-toolkit
(http://hannonlab.cshl.edu/fastx_toolkit/). This filtering step is optional, because often these
poor-quality reads are unable to align to the genome. The remaining reads were aligned to
the human reference genome (hg19) with Bowtie software 0.12.7 (Langmead et al. 2009),
allowing one mismatch (due to sequencing errors) and accepting only the best alignment
(with essential command line arguments: -v 1 -k 1 –m 1 –f –S –-best hg19). Bowtie is one of
the many sequence aligners (e.g. BWA, Mosaik, MAQ) and it has been proven to be fast and
accurate (Li & Homer 2010). These alignment reads (~50-100 million reads) were in the
Sequence Alignment/Map (SAM) format, which was converted to more compacted size
Binary Alignment/Map (BAM) format (with SAMtools) for further analysis.
Hypergeometric Optimization of Motif EnRichment (HOMER) software version 4.2 was
used in the downstream analysis (Heinz et al. 2010). HOMER is a command line program
(written in Perl and C++), which has multiple downstream analyses available for massively
parallel sequencing data. First, regions were identified that were enriched (peaks) in the
ChIP sample relative to the control (input/IgG) with statistical significance. There are
several software programs to identify peaks (e.g. MACS, PeakSeq, ZINBA) and the choice
of the method is highly dependent on the research question (sharp, broad or mixed region).
In the present case, the interest was on narrow peaks, which like AR, are produced by TFs.
Thus, the findPeaks program was used with a factor analysis strategy applying three fold
enrichment  over  an input  background read set  (own input  for  each cell  line).  In  addition,
there was an additional cut-off for selecting binding sites in which the normalized tag
counts were ?6. Detected binding sites were reported in a tab-delimited text file (BED-file),
which contained peaks location (chromosome and start and end coordinates)(Figure 5).
Matching the ENCODE Consortium guidelines, two independent biological replicates were
sequenced per sample and this gained ?10 million uniquely mapped reads per replicate
(Furey 2012). Binding site overlaps between each replicate pair which were identified using
BEDTools, also fulfilled the ENCODE requirements for replicate similarity (Quinlan & Hall
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2010). Initial overlap analysis of wtAR- or AR-2KR- expressing cell binding sites was
performed using BEDTools and non-shared binding sites were analyzed further using
getDifferentialPeaks command of HOMER using a cutoff of two-fold enrichment over the
other sample to identify the final preferred binding sites for wtAR- and AR-2KR-expressing
cells.  HOMER  was  also  used  for  genomic  annotation  of  peak  positions  and  to  normalize
reads to 107 for visualization: final chromatin tracks were done in Integrative Genomics
Viewer. DNA motif discovery was done with the findMotifsGenome program of HOMER
with motif lengths 6,10,15,20 covering ± 100 bp of the AR peak center. The association of
ARBs to nearby genes (±100 kb from the transcription start site) and androgen-regulated
genes was conducted with Anduril (Engine 1.2.18) with NextBioentity (Ensembl Homo
Sapiens 71.37) (Ovaska et al. 2010).
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5 Results and Discussion
5.1 SUMO MODULATES THE FUNCTION OF AR AND FOXA1
5.1.1 SUMOylation of AR and FOXA1
Due to the biological importance of the SUMO process, SUMOylation targets have been a
focus of great interest and the numbers of reported SUMO targets continue to increase
(Golebiowski et al. 2009, Hendriks et al. 2014, Tammsalu et al. 2014). Many TFs are known
to be covalently modified by SUMOs. When AR is ectopically coexpressed with SUMO-1, it
is SUMOylated in two “classical” consensus sites, lysines 386 and 520 (sites shown in
Figure 2)(Poukka et al. 2000, Kaikkonen et al. 2009). However, more biologically relevant
studies  with  endogenous  AR  will  be  necessary  to  confirm  the  results  from  transient
overexpression studies. Thus, co-immunoprecipitation assays revealed that androgen
exposure in VCaP cells induced endogenous AR modification by SUMO2/3 (Figure 1A in I).
Interestingly, the antiandrogen (bicalutamide) was not capable of inducing SUMOylation
or SUMO1 was not able to SUMOylate the endogenous AR. As VCaP cells contain ~8 times
more SUMO2/3 than SUMO1 protein (Figure A1 in I), the modification of AR by SUMO-1 is
probably very weakly detectable compared to the SUMO2/3 modification. Previously,
studies from our laboratory had shown that agonist-induced conformation of the AR
favored receptor SUMOylation (Kaikkonen et al. 2009). Since bicalutamide was not able to
induce SUMOylation, it seems that the agonist-induced conformational change is needed
before  one  can  have  any  formation  of  AR-SUMO  conjugates.  The  LBD  of  the  AR  is
important for SUMOylation, as LBD-deficient AR (with intact SUMOylation sites in NTD)
displayed no SUMOylation. This is probably due to the disruption of an interaction with
SUMOylation machinery components, such as PIAS proteins.
To  study  further  the  role  of  the  AR  SUMO  modification,  it  was  decided  to  generate
isogenic human embryonal kidney 293 (HEK293) cell lines stably expressing wtAR or AR-
2KR, in which SUMO acceptor sites, K386 and K520, were converted to arginine residues.
This double mutation abolished AR SUMOylation (Supplementary Figure S1A in II). These
embryonic kidney cells, however, lacked the expression of some traditional AR target
genes. Therefore, it was decided to continue the experiments with a PCa cell line, PC-3 cells,
which lack endogenous AR expression (Supplementary Figure S1B in II). Due to the PCa
origin, this model also better resembled the “natural” environment of AR function. The
effects of these mutations will be described in 5.1.2, 5.2.1 and 5.3.1 chapters.
New, proteome-wide methods for the identification of SUMO modification sites by mass
spectrometry have been developed (Tammsalu et al. 2015). These proteome-wide studies
have predicted that a number of the FOX family proteins are putative SUMOylation targets.
One of these studies (Golebiowski et al. 2009) provided a hint that FOXA1 could be a
SUMO2 target (in Hela cells). The function of the FOXA1 has been extensively studied, but
there were no previous reports of FOXA1 regulation by any PTM. Now Ni2+-chelate affinity
chromatography analysis revealed that when FOXA1 was ectopically coexpressed with
SUMOs, it was SUMOylated at least at two of its three consensus sites (lysines 6, 267 and
389,  shown in  Figure  4,  Figure  6)(Figure  1D in  III).  Interestingly,  a  single  mutation of  the
consensus sites did not affect FOXA1 SUMOylation and a double mutation of the consensus
sites changed the pattern of FOXA1 forms induced by SUMO-1, still leaving one
SUMOylated FOXA1 form (Figure 6). Thus, conversion of all three consensus site lysines to
arginines was required to abolish all the FOXA1 forms and yield SUMOylation-deficient
FOXA1 (FOXA1-3KR) (Figure 6) (Figure 1D in III).  Our previous studies have shown that
mutation of a single SUMOylation site can cause a shift of SUMOylation to some other site,
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possibly to a non-consensus, SUMOylation site (data not shown). The SUMOylation of
FOXA1  seems  to  differ  from  that  of  FOXA2,  where  SUMOylation  seems  to  occur  only  at
one site, K6 that is conserved in FOXA1 (Belaguli et al. 2012). Similarly to the situation in
AR,  FOXA1  SUMOylation  can  be  promoted  by  overexpression  of  the  SUMO  E3  ligase
PIAS1 and reversed by the SENP1 (Figure 3 in III)(Kaikkonen et al. 2009). Notably, the
present co-immunoprecipitation assays provided evidence for the modification of
endogenous FOXA1 in LNCaP cells by SUMO2/3 (Figure 1E in III).
Figure 6. FOXA1 is SUMOylated at least at two of its three SUMOylation consensus site lysines
(lysines 6, 267, 389). A) Wild-type (wt) FOXA and its mutants were expressed in COS-1 cells in
the  presence  and  absence  of  His6-tagged SUMO1 and His6-tagged proteins were isolated with
Ni2+-chelate affinity chromatography and immunoblotted with anti-FOXA1 antibody. B) A
simplified model depicting the effect of compound mutations on FOXA1 SUMOylation. Mutation
of the two consensus sites (marked with X) leaves one SUMOylated FOXA1 form.
In co-transfection-based studies, both TFs (AR, FOXA1) were shown to be SUMOylated
with both SUMO-1 and -2 paralogs and it appeared as if they were preferentially
SUMOylated by SUMO-1. However, when SUMO1 and SUMO2 were ectopically expressed
at comparable levels, de-conjugation of SUMO2 was more rapid, which may explain the
apparently more efficient SUMOylation with SUMO-1. This was demonstrated with
ectopically expressed deconjugation-defective SUMO1-94P and SUMO-2-90P mutants,
which revealed no difference in their conjugation (Supplementary Figure A2 in I and Figure
1C in III). The mechanisms regulating paralog-selective SUMOylation are poorly
understood,  albeit  SENPs  and  SUMO  E3  ligases  have  been  reported  to  play  a  role  in
SUMO-paralog selective modifications (Zhu et al. 2009). Due to the rapid turnover and
highly dynamic nature of SUMOylation, the steady-state level of endogenous SUMO
conjugates was very low, as is the case with the AR and FOXA1 (Figure 1A in I and Figure
1E  in  III).  Often  stimuli,  such  as  ligand  binding  or  HS,  are  needed  before  one  can  detect
endogenous SUMO conjugates. In contrast to the situation with co-transfection studies,
endogenous proteins were preferentially SUMOylated with SUMO2/3, which may be due
to the higher levels of this SUMO form in many cell types (Supplementary Figure A1 in I).
Since most of FOXA1 SUMOylation studies had been performed under overexpression
conditions, more studies with endogenous proteins will be needed to validate the
regulating role of the modification. Although the new, proteome-wide analysis of SUMO
substrates can obtain data from more natural environments, the identification of SUMO-
acceptor lysines in an entirely endogenous fashion is still challenging.
Recent studies, especially proteome-wide SUMOylation analysis, have revealed that HS
could trigger rapid conjugation of SUMO2/3 to proteins (Saitoh & Hinchey 2000,
Golebiowski et al. 2009, Niskanen et al. 2015). These HS SUMOylated proteins are involved
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in many biological functions, e.g. cell cycle regulation, apoptosis, folding and transcription.
Additionally, SUMO2/3 promoted cell survival, as depletion of SUMO2/3 caused a
reduction in cell survival after exposure to HS (Golebiowski et al. 2009). In the case of the
AR, it was observed that in addition to androgen exposure, stress triggered AR
SUMOylation. Exposure of the VCaP cells to heat (43 °C) evoked the accumulation
especially of the SUMO2/3 modified AR (Figure 1B, D in I). This stress-triggered AR
SUMOylation was reversible, when cells were returned to 37?C, the SUMO conjugates
quickly (within 15 min) disappeared (Figure 1C in I). Studies with heat-stressed wtAR or
AR-2KR expressing cells confirmed that the HS-induced SUMO2/3 modification of AR was
largely  focussed on the  receptor´s  major  SUMO acceptor  lysines  (Figure  2A in  I).  Further
studies showed that the modification was associated with the movement of the AR between
the nucleoplasm and the nuclear matrix (Figure 3 in I). HS had more pronounced nuclear
matrix-tethering effects on the AR-2KR than wtAR. These results suggest that SUMOylation
is important for the nucleoplasmic solubility of the AR, especially under stress conditions,
and that it protects the receptor from proteotoxic insults in the nucleus. The HS-induced
accumulation of endogenous AR-SUMO conjugates may be partly due to the inhibition of
SENPs during HS.
Other  stresses  (high  osmolarity  and  heavy  metal  ions)  also  induced  AR  SUMOylation,
although with slightly different magnitudes (Supplementary Figure A3 in I). Later, milder
stress (electrophilic stressor, prostaglandin 15d-PGJ2)  was  shown  to  induce  AR
SUMOylation (Kaikkonen et al. 2013). However, HS did not induce FOXA1 SUMOylation
(data not shown). Thus, the response to HS appeared to be substrate specific. Similarly,
Golebiowki and co-workers demonstrated that although SUMO-conjugates generally
accumulated during HS, some substrates showed reduced or unaltered levels of
SUMOylation.  HS-triggered SUMOylation could be attributable to either the inhibition of
SUMO proteases or the activation of SUMO ligases. Recently loading of PIAS1 onto
chromatin was reported to be activated by HS (Niskanen et al. 2015). Since alterations in
cell functions during carcinogenesis can induce stress responses, the stress-triggered
SUMO2/3 modification of AR and its coregulators may contribute to the deregulated
androgen signaling encountered during prostate carcinogenesis.
5.1.2 SUMOylation regulates proteins´ mobility and stability
SUMOylation has been shown to regulate the targeting of several proteins to the nucleus,
even to subnuclear domains (Heun 2007). The two studied proteins, FOXA1 and agonist-
bound AR, were both localized into nucleus and disruption of their SUMOylation sites did
not change their localization (Supplementary Figure 1C in II and Figure 4 in III). Thus,
modification did not exert any apparent effect on AR´s or FOXA1´s subcellular localization.
FOXA1 and AR have been shown to physically interact but disruption of neither AR´s nor
FOXA1´s SUMOylation sites affected this interaction (data not shown)(Toropainen et al.
2015). Interestingly, the ligands of the AR have been shown to influence the co-localization
of  AR  and  FOXA1  in  the  nucleus,  with  a  pure  agonist  demonstrating  the  strongest  co-
localization (Belikov et al. 2013).
SUMOylation is known to alter the nuclear mobility of TFs (Tirard et al. 2007).  A
comparison of intranuclear mobility of the wild-type and SUMOylation-deficient forms by
fluorescence recovery after photobleaching (FRAP) assays indicated that SUMOylation
could modulate the nuclear mobility of the AR and FOXA1. Agonist-bound SUMOylation
deficient AR displayed retarded mobility compared to wtAR (Figure 4 in I). This may have
been due to translocation of AR into different subnuclear compartments not detectable in
traditional microscopy-based imaging. Similarly, disruption of SUMOylation sites retarded
the nuclear mobility of FOXA1 (Figure 4A, 4C, in III). Interestingly, co-expression of the AR
with wild-type FOXA1 (wtFOXA1) or FOXA1-3KR reduced this difference. However,
FOXA1  co-expressed  with  AR  retarded  the  AR´s  movement,  and  SUMOylation  site
deficient FOXA1 had a stronger retarding effect on the AR mobility (Figure 4B, 4D in III).
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These results suggest that the mobility of FOXA1 and AR may be regulated by the extent of
SUMOylation on the pioneer factors.
SUMOylation  has  been  shown  to  modify  the  stability  of  many  proteins  (Rytinki  &
Palvimo 2008, Rytinki & Palvimo 2009). The effect of SUMOylation on the stabilities of AR
and the FOXA1 protein was investigated by exposure of the cells to the protein synthesis
inhibitor, cycloheximide. In the case of AR, SUMOylation prolonged the AR half-life in the
nucleus, as the SUMOylation-deficient AR mutant exhibited a decreased lifespan compared
with  wtAR  (Figure  2B  in  I).  Our  HS  studies  implied  that  SUMOylation  may  have  a
protective function and that SUMOylation doed not prime the AR for degradation, as has
been reported to  be  the  case  for  some proteins  such as  PML,  DNA damage factor,  MDC1
and FLICE-associated huge protein, but the PTM may have protected the receptor from
degradation (Uzunova et al. 2007, Luo et al. 2012, Vennemann & Hofmann 2013). In
contrast to the situation with AR, the mutation of the SUMOylation sites stabilized FOXA1,
i.e. the SUMO-deficient FOXA1 exhibited greater stability than its wild-type counterpart,
wtFOXA1 (Figure 2 in III).
5.2 AR CHROMATIN BINDING
The latest techniques make it possible to investigate the TF´s targets at the level of the
whole genome instead of examining only a few interesting candidate genes or a single gene
locus. ChIP-seq studies have revealed tens of thousands of ARBs across the human genome
and thus it appears that a mere few percent of computationally predicted binding sites on
chromatin are occupied. ARBs are preferentially located in the intronic and intergenic
regions (Sahu et al. 2011, Massie et al. 2011, Chng et al. 2012). Similarly in the present study,
most of the ARBs were localized to introns or were intergenic, and only a very small
proportion was found in the proximal promoter regions (Figure 4C in II). This indicates
that AR primarily binds to distal enhancers that can be from several kb to over 100 kb
distant from the promoter regions of the target genes.  Based on a de novo motif analysis,
about 60 % of the ARBs contain a classical ARE motif, which was the most relevant motif
(Figure 6B in II) (Massie et al. 2011, Toropainen et al. 2015).
In addition to ARE, AR binding to chromatin is regulated by coregulators and/or pioneer
factors. One pioneer factor, FOXA1, is known to interact with the AR in prostate, and
depletion  of  FOXA1  has  led  to  a  global  redistribution  of  ARBs  and  more  specific  AR
binding to ARE motifs (Sahu et al. 2011). Interestingly, disruption of SUMOylation sites
seemed to affect FOXA1´s binding to chromatin. Based on the present qChIPs, binding of
FOXA1-3KR to LRIG, MERTK and PSA loci  was  more  efficient  than  that  of  wtFOXA1,
which could reflect the retarded nuclear mobility of FOXA1-3KR (Figure 6B in III).
Interestingly, the more efficient FOXA1-3KR binding correlated with increased expression
of analyzed AR target genes (Figure 6 in III). AR function can therefore be regulated by
PTMs in a pioneer factor, and this may have bearing on the future therapy of PCa, i.e.
FOXA1 has been shown to have a role in PCa progression mainly due to its activity on AR-
dependent expression of genes important in cell proliferation and survival.
The amount of ARBs in different PCa cell lines has varied between studies
(Supplementary Figure 7D). This difference could be explained by cell-type differences,
different ligands and treatment times, as well as the variety of analytical techniques
employed (described in chapter 4.1.3).  Even within the same cell line, cell density and
culture conditions are known to alter steroid responsiveness. Moreover, VCaP cells have an
AR gene amplification, which seems to correlate with higher amount of ARBs. Different cell
lines may also display a different pattern of coregulators, which guide AR binding. For
instance,  in  comparison  to  PC-3  cells,  LNCaP  and  VCaP  cells  ARBs  had  more  often  a
FOXA1  motif  close  to  their  ARBs,  and  they  similarly  expressed  more  FOXA1
(Supplementary Figure 10 in II). A recent study showed that genome-wide ARBs in human
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normal prostate epithelium and a tumor tissue sample differed considerably, illustrating
reprogramming during prostate epithelial transformation (Pomerantz et al. 2015). Although
ARBs from LNCaP and VCaP formed distinct subsets, they revealed a strong concordance
with cancerous prostate tissue ARBs. Similarly as in PCa cell lines, FOXA1 co-occupied
with ARBs in human prostate tumor tissue (Pomerantz et al. 2015). In vivo ChIP-seq
profiling of ARBs in prostate,  epididymis and kidney showed interestingly only a modest
overlap, highlighting tissue-specificity of the binding sites (Pihlajamaa et al. 2014).
A variety of different factors regulate AR chromatin binding and it was demonstrated
here that cell stress could influence AR chromatin binding. Cell stress rapidly detached AR
from the regulatory regions of TMPRSS2, SPOCK1 and S100P, as  shown  with  qChIPs
(Figure 5 in I). During the recovery period (cells were returned to 37°C growth conditions),
the  AR  was  capable  of  returning  to  chromatin.  HS  also  suppressed  the  expression  of  AR
target genes (Supplementary Figure A4 in I). Interestingly, HS induced a reversible
accumulation of SUMOylated AR into the nuclear matrix compartment which seemed to be
enriched in SUMOylation pathway components (Figure 3B, 3C in I) (Heun 2007). Similarly
to HS, exposure to a mild stress (prostaglandin 15d-PGJ2) inhibited AR binding to
chromatin (Kaikkonen et al. 2013). Taken together, it is concluded that stress conditions can
detach the AR from its chromatin binding sites, targeting it to the nuclear matrix fraction,
resulting in a repression of AR target gene expression (Figure 3, 5 in I).
5.2.1 SUMOylation affects AR´s chromatin binding
We determined how SUMOylation of AR could influence its genome-wide chromatin
binding in genuine chromatin environment using PC-3 and HEK293 cells that stably
expressed either wtAR or AR-2KR. Preliminary results in HEK293 cells by qChIPs
predicted that the accumulation of S100P and SPOCK1 mRNAs  in  stably  AR-2KR
expressing  cells  was  in  line  with  more  extensive  AR-2KR  loading  onto  the  regulatory
regions of these genes after androgen induction (Figure 7 in I). Further genome-wide
studies  revealed that  there  was a  considerable  overlap in  the  wtAR and AR-2KR binding
sites (shared ARBs), although ~10% of the ARBs were non-shared binding sites (wtAR- and
AR-2KR-preferred sites) (Figure 4A, 4B in II). Recruitment of hormone-bond AR to genomic
binding sites is thus not dramatically different between wtAR and AR-2KR. The receptor
type-preferred androgen target genes were not clearly associated with wtAR and AR-2KR
preferred ARBs. Some androgen-regulated loci had binding differences between wtAR and
AR-2KR, but the differences between wtAR and AR-2KR binding alone were insufficient to
explain the observed differences in their transcript levels (Figure 5 in II). Recently a similar
study with GR revealed a correlation between wild-type GR and SUMOylation-deficient
GR chromatin occupancy with the expression of several growth-related target genes
(Paakinaho et al. 2014). The differences in the sampling time points in the present study
(RNA profiling 20 h and ChIP-seq 1 h) compared to those used by Paakinaho et al. (RNA
profiling 6 h and ChIP-seq 1 h) could explain different correlation of the gene expression
with  the  chromatin  binding  data.  Thus,  conducting  a  time  series  experiment  would  have
given a broader view. In addition, GR´s regulatory characteristics and target genes differ
from those of AR, which could explain the difference in the response. Moreover, HEK293
cells  are  a  suitable  model  for  GR,  as  they  contain  low  levels  of  endogenous  GR  and
probably therefore offer a more natural chromatin environment for the GR with all its
“normal” collaborating factors.
Binding  motif  analysis  of  identified  ARBs  can  provide  a  clue  which  other  TFs  can  co-
occur with the AR on chromatin. In PC-3 cells, ARE, ERG, FOXA1, C/EBP and AP-1 motifs
were identified as being significantly enriched within or close to ARBs (Figure 6A, 6B in II).
Interestingly, there were no differences in the number of AREs between the wtAR- and the
AR-2KR preferred ARBs, although AR-2KR has been shown to have enhanced activity on
promoters containing double AREs (Poukka et al. 2000). The ERG motif was similarly
enriched in all ARBs, but there was a significant difference in the enrichment of some other
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TF binding motifs: FOXA1 and C/EBP were found more often within the wtAR- preferred
ARBs, whereas the AP-1 motif was more enriched in the AR-2KR-preferred ARBs (Figure
6B, 6C, in II). An analysis of the motifs in HEK293 ARBs revealed similar differences in
preferred ARB-enriched motifs, but there were also cell-specific differences (Supplementary
figure 12 in II). SUMOylation sites are located in the NTD, which is important in mediating
their interactions with coregulators. Based on the motif analysis, it appeared that
SUMOylation could influence the AR chromatin occupancy and target gene selection via
regulating interactions with other TFs (e.g. FOXA1 and AP-1) in nearby chromatin regions.
This together with the interaction with the coregulators may enhance or weaken AR
binding to the chromatin.
SUMOylation machinery components are known to modulate AR-dependent
transcription.  The experiment with qChIP-arrays revealed that SUMOylation machinery
components,  SUMO2/3  and  PIAS1,  co-occupied  with  AR  in  the  regulatory  regions  of  the
AR target genes, TMPRSS2, SPOCK1 and S100P, in VCaP cells (Figure 6 in I). Based on re-
ChIP analysis, chromatin bound AR seemed to be conjugated by SUMO2/3 or to be closely
associated with other SUMOylated proteins. Moreover, SUMOylation appeared to be
involved in the dynamics of the interactions between AR and chromatin.  Recent, genome-
wide ChIP-seq studies in VCaP cells have revealed that practically all PIAS1-binding sites
overlap with AR in androgen-exposed cells (Toropainen et al. 2015). These genomic sites
shared by PIAS1 and AR were also generally localized by SUMO2/3 and also interestingly
by FOXA1. Thus, the genome-wide binding data are in good agreement with the present
qChIP data (Figure 7). Although similar results can be obtained with both techniques, the
amount of data and the accuracy of the location of binding sites is far superior with ChIP-
seq. PIAS1 is the major PIAS protein in VCaP cells and its expression was upregulated by
exposure to androgens (Supplementary Figure A5 in I). Interestingly, PIAS1 depletion
showed a gene-selective effect on the chromatin binding of AR, implying that this protein
plays a role in regulating AR target genes in PCa cells (Figure 6 D in I).  Moreover, recent
transcriptome profiling analyses have confirmed that PIAS1 depletion affected androgen-
regulated genes in a target gene selective manner (Toropainen et al. 2015). Therefore, PIAS1
seems  to  possess  a  role  in  defining  AR´s  transcriptional  programs.  Recently,  PIAS1
expression has been shown to correlate with AR expression in primary prostate tumors,
and high PIAS1 expression is an indicator of reduced relapse-free survival (Puhr et al.
2015).
Figure 7. Co-occupancy of the AR, FOXA1 and SUMOylation pathway components on chromatin.
ChIP-seq  track  examples  of  two  androgen  regulated  loci,  S100P  and  TMPRSS2,  show  AR-,
PIAS1-, SUMO2/3- and FOXA1-binding events in VCaP cells in the absence (-) and presence (+)
of androgen. Red arrows indicate the location of qChIP primers.
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Figure 8. Comparison of genomic SUMO2/3-binding sites in several cell lines shows cell line-
specific  patterns.  A)  Chromatin  environment  of  AR  (black  bar)  and  SUMO2/3  (green  bar)
binding sites in PC-3 cells expressing wtAR or SUMOylation site mutant AR (AR-2KR). Only a
small proportion of binding sites are common (pink bar). Binding sites were further categorized
to wt-preferred (red bar), shared (brown bar) and SUMOylation site mutant-preferred (2KR)
(blue bar).  Heat map showing AR- and SUMO2/3-binding site signals  in ± 2 kb window using
fire-color scale. B) Venn diagram showing distinct genomic SUMO2/3-binding sites in PC-3 and
VCaP PCa cells and GR-expressing HEK293 cells.
Due to the co-occupancy of AR and SUMO2/3 on chromatin of VCaP cells, the next
experiments involved ChIP-seq analyses with anti-SUMO2/3 antibody in wtAR and AR-
2KR expressing PC-3 cells in the presence of androgen. The sequence reads of two
biological replicates were analyzed in the same way as the AR data to identify peaks
representing SUMO2/3-enriched binding sites. Interestingly, these genome-wide analyses
revealed that SUMO2/3 was enriched almost similarly in wtAR and AR-2KR expressing
cells (Figure 8A, green bar). A comparison of the overlap between ARBs and SUMO2/3
enriched binding sites indicated that there was only ~10% co-occupancy (Figure 8A, pink
bar). However, mutation of the SUMOylation sites in GR changed the genome-wide
SUMO2/3-binding pattern in HEK293 cells and agonist-bound GR in these cells showed a
considerable overlap with the SUMO2/3-binding sites (Paakinaho et al. 2014). Similarly,
agonist-bound AR in VCaP cells showed an overlap with SUMO2/3 binding sites
(Toropainen et al. 2015). Thus, it appears that the AR in generated stable PC-3 cell lines
cannot fully recapitulate the AR target genes’ expression pattern of the natural AR protein
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in PCa cells. The poor overlap between the ARBs and the SUMO2/3-binding sites in PC-3
cells may imply that there are other major SUMO2/3 acceptor proteins on chromatin. It is
becoming evident that the function of SUMO2/3 on chromatin is cell-type specific (Figure
8B) (Neyret-Kahn et al. 2013, Niskanen et al. 2015).  Similarly, proteome-wide SUMO target
studies identified cell line-specific targets (Hendriks et al. 2014). Thus, the cell background
seems to have a major impact in pinpointing SUMOylation targets, and many
SUMOylation targets remain to be discovered from more cell type-specific SUMOylation
studies.  Recent  studies  have  indicated  the  global  chromatin  binding  dynamics  of
SUMOylation pathway components and demonstrated the complexity and diversity of the
functions that the chromatin-associated SUMO may exert on gene expression (Paakinaho et
al. 2014, Niskanen et al. 2015, Seifert et al. 2015, Toropainen et al. 2015).
5.3 SUMOYLATION-REGULATED GENE PROGRAMS
5.3.1 Genome-wide role of SUMOylation in the AR´s transcriptional activity
SUMOylation has been shown to regulate SR’s transcriptional activity with often the
modification being linked to transcriptional repression (Poukka et al. 2000, Treuter &
Venteclef 2011). This assumption has been most often based on simple reporter gene assays.
For instance, the disruption of the AR SUMOylation sites increased the transcriptional
activity of AR on ARE-driven simple promoters in reporter gene assays. In particular,
SUMO modifications reduced the transcriptional potency of the receptor on promoters
containing tandem AREs (Poukka et al. 2000, Kaikkonen et al. 2009). It was decided to
investigate the effect of AR SUMOylation on endogenous target gene expression in a
genuine chromatin environment using PC-3 and HEK293 cells that stably expressed either
wtAR or AR-2KR. Reporter gene assays with these stable cell lines displayed a similar
transcriptional repression as seen previously (Supplementary Figure S1D in II). In the
preliminary studies, the expressions of a few AR target genes (S100P, SPOCK1, MAFB and
FOXA4) were analyzed in isogenic HEK293 cells (Figure 7A in I). The results indicated that
SUMOylation sites did not simply repress the AR activity on all target genes, instead the
effect of SUMOylation on the AR activity was target gene specific.  Similarly, an unbiased
genome-wide gene expression analysis in PC-3 and HEK293 cells revealed three classes of
AR target genes with respect to their sensitivity to SUMOylation: enhanced (require the
SUMOylation sites, being robustly androgen-activated only in the wtAR cells), repressed
(androgen-regulation inhibited by SUMOylation, demonstrated by the enhanced
expression in the AR-2KR cells) or neutral (insensitive to the AR SUMOylation sites, being
similarly expressed in both cell lines) (Figure 1B, 1C and Supplementary Figure S3B and C
in II). Generally, more genes were regulated in wtAR cells than in the AR-2KR cells (Figure
9A) (Figure 1A, Supplementary figure 3A in II).
A comparison of androgen-regulated genes in several PCa cell lines demonstrated the
presence of a considerable overlap, although also clear evidence for cell-specificity could be
observed (Figure 9B)(Supplementary figure 2 in II) (Sahu et al. 2011, Toropainen et al. 2015).
In particular, androgen-regulated genes in PC-3 and HEK293 cell lines exhibited a distinct
pattern (Figure 9A). As these results indicate, the most commonly used and long
established cell culture models of PCa have different biological properties (Peehl 2005,
Pomerantz et al. 2015). Therefore, generalization of results from only one cell line needs to
be done with caution and preferably several cell lines should be used and compared. In
addition, it seems that the AR chromatin binding per se differs much less between PCa cell
lines and tissue samples than the corresponding situation with the AR-regulated genes.
This  indicates  that  other  TFs  are  critically  involved  in  determining  the  specificity  of  AR-
mediated gene regulation. In addition, some differences in androgen-regulated genes
could, at least in part, have been attributable to the different treatments and data analyses.
The present results also show that PC3 cells can, at least at some level, be reprogrammed to
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androgen-dependence by overexpressing AR. Similarly, SUMOylation has been reported to
modulate the target gene selection of PR and GR (Knutson et al. 2012, Paakinaho et al.
2014). Therefore, SUMOylation of SRs is not simply repressive as previously suggested by
simple reporter gene assays, but rather it can either activate or suppress gene expression in
a target gene selective fashion.
Figure 9. Comparison of androgen-regulated genes in different cell lines shows cell-specificity.
A) Venn diagram showing distinct patterns of androgen-regulated genes in wild-type AR (wtAR)
and  SUMOylation  deficient  (AR-2KR)  expressing  PC-3  and  HEK293  cells.  B)  Venn  diagram
showing distinct patterns of androgen-regulated genes in different PCa cells.
According to the pathway enrichment analysis, the differentially expressed genes due to
AR SUMOylation were enriched in the categories of movement, development, cell death
and survival, cell morphology, and growth and proliferation (Figure 2A in II). Cell
proliferation  and  cell  death  and  survival  pathway  predictions  were  shown  to  be
biologically relevant, as cells expressing SUMOylation-deficient AR proliferated more
rapidly  and were  more sensitive  to  apoptosis  than wtAR-expressing cells  (Figure  3  in  II).
These biological pathway analyses highlight the difference in transcriptional regulation by
wtAR  and  AR-2KR  upon  androgen  stimulation.  Accordingly,  SUMOylation  similarly
regulated PR and GR activity on genes influencing cell proliferation. In addition, it has been
reported that a mutation in MITF that impairs its SUMOylation, increases the expression of
MITF target genes which are associated with cell growth, proliferation and inflammation
(Bertolotto et al. 2011). Interestingly, this is linked to the risk of developing melanoma
or/and renal cell carcinoma. Furthermore, disruption of SF-1 SUMOylation in mice has been
linked to abnormal Hedgehog signaling and endocrine development (Lee et al. 2011).
5.3.2 SUMOylation regulates the transcriptional activity of FOXA1
It seems that SUMOylation can repress the transcriptional activity of FOXA1. The activity
of the reporter gene with FOXA1-3KR was elevated by approximately 4-fold compared
wtFOXA1, suggesting that SUMOylation sites have a negative effect on the transactivation
potential of FOXA1 (Figure 5A in III). However, as discussed above, the role of
SUMOylation is not that so straightforward as may be implied from reporter gene assays.
Several studies have shown that the effect of SUMOylation on the SR activity is target gene
specific, and probably genome-wide studies with FOXA1 will reveal that SUMOylation also
has a target gene specific role in FOXA function.
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Since  FOXA1  is  an  important  pioneer  factor  for  AR,  it  was  decided  to  examine  the
importance of FOXA1´s SUMOylation sites in the context of AR signaling.  When both
FOXA1 forms were overexpressed in LNCaP PCa cells, it was noted that FOXA1-3KR was
more active than wtFOXA1 in increasing the androgen-induced expression of some AR
target genes (LRIG1, MERTK and PSA) analyzed by RT-qPCR (Figure 6A in III). This data
therefore suggest that the FOXA1´s SUMOylation sites can modulate the pioneer activity of
FOXA1 on AR-dependent  transcription in  PCa cells.  As  the  mutation of  neither  AR´s  nor
FOXA1´s SUMOylation sites affected their mutual interaction, this effect could be mediated
via altered chromatin binding. Overexpression of wtFOXA1 increased cell proliferation in
LNCaP cells in agreement with the data from Robinson and co-workers whereas
interestingly, SUMOylation-deficient FOXA1 was not capable of enhancing cell
proliferation (Figure 8 in III)(Robinson et al. 2013a). Thus, similarly to the SUMOylation of
other TFs, FOXA1 SUMOylation seems to control many genes related to cell proliferation.
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6 Conclusions and Future Prospects
SUMOylation is essential for the normal physiology of living organisms, and as new
SUMOylation targets are identified, this modification is linked to new biological functions
and  diseases.  Many  of  the  TFs  and  coregulators  are  known  to  be  regulated  by
SUMOylation.  SUMOylation  was  thought  to  repress  AR  transcriptional  activity  and  until
recently, very little was known about the genome-wide role of SUMOylated transcriptional
regulators.  In  this  thesis,  the  role  of  SUMOylation  in  AR  function  was  investigated  in
human PCa cells and stable cell lines expressing either wtAR or SUMOylation-deficient AR.
This thesis utilized modern genome-wide approaches (microarray and ChIP-seq), which
enabled an unbiased analysis of the AR-chromatin occupancy and expression of androgen-
regulated genes. It is essential to expand our knowledge of the properties of the AR and its
regulation in PCa cells, especially in a genuine chromatin milieu before we can gain a better
understanding of the molecular mechanisms underlying PCa development. AR function is
tightly regulated by other TFs, including the pioneer factor, FOXA1. The function of the
FOXA1 has been extensively studied and linked to PCa development, but there were no
previous reports investigating how PTMs could regulate the properties of FOXA1.
The following conclusions can be drawn from the individual studies of this thesis:
? SUMO  modification  influences  AR  transcriptional  activity  in  many  ways,  i.e.
positively, negatively or in a neutral fashion, in a target gene and pathway selective
manner.
? SUMOylation affects the dynamics of AR-chromatin interactions and recruitment of
other TFs to AR-binding chromatin sites.
? Androgens induce the SUMO2/3 modification of endogenous AR in PCa cells.
? Stress triggers the accumulation of SUMO2/3-modified AR, detaches the AR from its
chromatin binding sites and targets the receptor into the nuclear matrix
compartment, resulting in a down-regulation of AR target gene expression.
? SUMOylation regulates the transcriptional activity and chromatin occupancy of
FOXA1. This modulates the activity of the FOXA1 on AR-dependent transcription in
PCa cells.
This thesis provided new information on how SUMO-modification regulates the
function of both AR and FOXA1. SUMOylation had an impact on the proteins´ stability,
intranuclear mobilities, chromatin interactions, and target gene expressions (Figure 10). A
shift from pure overexpression data to studies of endogenous proteins should provide a
more realistic perspective view of the AR-mediated gene regulation. Nowadays, with the
help  of  novel  genome  editing  tools,  like  TALEN  (Transcription  Activator-Like  Effector
Nucleases) and CRISPR (Clustered, Regularly Interspaced, Short Palindromic Repeats) AR
could be engineered as a SUMOylation-deficient form into LNCaP or VCaP cells, which
would  make  it  possible  to  examine  the  role  of  SUMOylation  in  an  even  more  “natural”
chromatin environment. Similarly these genome editing tools could be used to study the
role of FOXA1 SUMOylation in a natural way. During this thesis, massively parallel
sequencing  technologies  have  expanded  the  experimental  possibilities  for  studying  the
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genome-wide regulation of transcription. These techniques, like RNA- and global run-on
(GRO)-seq, will be crucial in collecting new information about the role of SUMOylation in
AR  and  FOXA1  function.  In  the  future,  on-going  animal  model  studies  with  knock-in  of
SUMOylation-deficient AR in mice will expand our knowledge of the role of SUMOylation
in AR function in vivo.
Figure 10. A schematic model presenting the role of the SUMOylation in AR function in PCa cells.
SUMO-modification  regulates  AR´s  stability  and  intranuclear  mobility.  SUMOylation  has  an
impact on AR chromatin binding and it seems to influence interactions of AR with other TFs and
therefore target gene expression. Furthermore, FOXA1 is SUMOylated. Additionally, stress
triggers accumulation of SUMO2/3-modified AR, detaches the AR from chromatin,  and inhibits
AR target gene expression. (wtAR; wild-type AR, AR-2KR; SUMOylation-defective AR, S2/3;
SUMO2/3).
PCa diagnosis and CRPC treatment are still tremendous challenges. It is important to
identify mechanisms that promote castration resistance in order to be able to design more
effective therapeutic strategies. Similarly, new biomarkers that correlate with aggressive
tumors are needed. The present experiments have revealed new possibilities to regulate AR
activity which could open up, in the long term, new prospects for PCa therapy. Hopefully,
in the future new techniques, like single-cell/molecule analyses can be used to guide
patient-specific treatment.
In the last decade, genome-wide techniques have shifted TF studies away from the single
gene  to  the  whole  genome  level.  As  new  techniques  are  replacing  old  methods,  the  next
challenge  will  be  to  make  sense  of  the  huge  amount  of  data  which  these  new  methods
(ChIP-seq, RNA-seq, DHS-seq, FAIRE-seq, GRO-seq, and HiC) can produce. In this way, it
will be possible to devise new concepts of the process of gene regulation and perhaps
reveal the “cofactor code” that defines each cell type and state.
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